I3Y-MC-JPCB Protocol (d) 
 
Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450    
(CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients 
 
NCT0 2688088 
 Approval Date: 22- Sep-2016 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 1
Abemaciclib (LY2835219)1.Protocol I3Y -MC-JPCB (d)
Effects of Multiple Doses of A bemaciclib on the 
Pharmacokinetics of Cy tochrome P450 (CYP) 1A 2, CYP2C9, 
CYP2D6, and CYP3A  Substrates (Caffeine, Warfarin, 
Dextromethorphan, and Midazolam) in Cancer Patients
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
abemaciclib (LY2835219), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.
Note to Regulatory Aut horities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United St ates, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries. 
Abemaciclib (LY2835219)
This Phase 1 study is an open -label, 4-period, fixed -sequence study to investigate the 
effect of abemaciclib on pharmacokinetics of caffeine (CYP1A2 substrate), warfarin 
(CYP2C9 substrate), dextromethorphan (CYP2D6 substrate), and midazolam (CYP3A 
substrate) in patients with adva nced and/or metastatic cancer, followed by a safety 
extension phase.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly:  06 October 2015.
Amendm ent (a) Electronically Signed and Approved by Lilly:  2 1 December 2015
Amendm ent (b) Electronically Signed and Approved by Lilly:  25 January 2016
Amendm ent (c) Electronically Signed and Approved by Lilly :  24 March 2016
Amendm ent (d) Electronically Signed and Approved by Lilly
on approval date provided below .
Approval Date: 22-Sep-2016 GMT
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 2
Abemaciclib (LY2835219)2.Synopsis
Oncology Protocol Synopsis:  Study I3Y -MC-JPCB
Name of Investigational Product:
Abemaciclib (LY2835219)
Title of Study:  Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 
1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in 
Cancer Patients
Number of Planned Patients:  Up to 48 patients may be 
enrolled in order that 22 patients complete Periods 1 and 2.Phase of Development: 1
Length of Study:   
Screening:  Upto 30 days
Period 1:  7 days 
Period 2:  12 days
Periods 3 & 4:  16 & 28 days, respectively
Safety extension:  Patients are allowed to continue receiving abemaciclib in 28 -day cycles until disease progression 
or other reason for discontinuation per investigator’s assessment.
Objectives:   
The primary objective of this study is to assess the effect of abemaciclib on the pharmacokinetics (PK) of caffeine 
(CYP1A2 substrate), warfarin (CYP2C9 substrate), dextromethorphan (CYP2D6 substrate), and midazolam 
(CYP3A substrate) in cancer patients after multiple oral doses of abemaciclib.
The secondary objectives of this study are:
tocharacterize the tolerability of coadministration of abemaciclib with caffeine, warfarin, 
dextromethorphan, and midazolam following multiple doses of abemaciclib in cancer patients.
to assess the effect of abemaciclib on blood pressure and pulse rate foll owing multiple doses of 
abemaciclib in cancer patients.
The exploratory objectives of this study are:
to determine the effect of abemaciclib on the pharmacodynamics (PD) of a single dose of warfarin as 
measured by international normalized ratio (INR).
to assess the effect of abemaciclib on markers of renal function, including creatinine, cystatin -C, kidney 
injury  molecule -1 (KIM -1), and neutrophil gelatinase -associated lipocalin (NGAL).
to characterize bowel habits via a patient diary and a stool assessment tool (Bristol Stool Chart). 
to characterize diarrhea experienced via patient reported outcome data based on selected individual items 
from existing patient reported outcomes (PRO) scales (FACIT -D) as well as custom -generated PRO 
items.
Study Design:   
This will be an open -label, four -period, fixed -sequence study, followed by a safety extension phase, in patients 
with advanced and/or metastatic cancer.  
The drug cocktail of 100 mg caffeine, 10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazolam wil l be 
administered orally as a single dose on 2 occasions: Day 1 in Period 1, and in combination with abemaciclib on 
Day 8 of Period 2, after 7 days of 200 mg abemaciclib ever y 12 hours (Q12H) dosing.  After completing Period 2, 
patients will continue to re ceive abemaciclib at a dose of 200 mg Q12H (or a modified dose) through the end of 
Periods 3 and 4, in 28 -day cycles, and then may continue in a safety extension phase until discontinuation criteria 
are met.  
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 3
Abemaciclib (LY2835219)Diagnosis and Main Criteria for Inclusion and Exclusion:   
Patients may be included in the study if they meet the following criteria: have histological or cytological evidence 
of a diagnosis of cancer that is advanced and/or metastatic; are ≥18 years of age; have adequate organ function; 
have a performance status of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale; and have discontinued 
all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, cancer -related ho rmone 
therapy , and investigational therapy) for at le ast 21 days for myelosuppressive agents or 14 days for 
nonmyelosuppressive agents prior to receiving study drug and have recovered from the acute effects of therapy 
(treatment related toxicity resolved to baseline), except for residual alopecia.
Investigational Product, Dosage, and Mode of Administration:   
Abemaciclib
Abemaciclib will be supplied as 50 -mg capsules as the 25% w/w formulation (C3) for oral administration.
Drug Cocktail
This will include: commercially available caffeine citrate solution (20 mg/mL) for oral administration; 
commercially available warfarin (brand name Coumadin) as 5 -mg tablets for oral administration; commercially 
available dextromethorphan as 15-mgliquid gel capsules for oral administration; and commercially available 
midazola m sy rup (2 mg/mL) for oral administration. 
Planned Duration of Treatment:   
Period 1
On Day  1,10 mL of 20-mg/mL caffeine citrate solution , 2 × 5-mg tablet sof warfarin, 2 × 15- mgliquid gel 
capsules of de xtromethorphan, and 0.1 mL of 2 -mg/mL midazolam syrup will be coadministered
Period 2
On Day s 1 to 12, 4 × 50- mg capsule of abemaciclib will be administered orally in the morning and evening.  On 
Day 8, abemaciclib will be coadministered with 10 mL of 20 mg/mL caffeine citrate solution , 2 × 5-mg tablet sof 
warfarin, 2 × 15- mgliquid gel capsules of de xtrometho rphan, and 0.1 mL of 2 -mg/mL midazolam syrup.
Periods 3, 4 ,and Safety Extension Phase
Patients receive an abemaciclib dose of 200 mg Q12H (or modified dose as applicable) on a 28 -day cycle until 
discontinuation criteria are met.
Criteria for Evaluation:   
Safety:   Adverse events (AEs), clinical laboratory evaluations, vital signs, ambulatory blood pressure monitoring 
(ABPM), electrocardiograms (ECGs), bowel habits, renal function markers, and CYP genotyping.
Bioanaly tical:   Plasma concentrations of caffeine, S -warfarin, dextromethorphan, midazolam, and abemaciclib.  
Pharmacokinetic:   The primary parameters for analysis will be maximum observed drug concentr ation (C max), 
area under the concentration versus time curve from zero to infinity (AUC[0 -∞]), and time of maximum observed 
drug concentration (t max).
Efficacy:   Tumor assessments .
Evaluation Methods:   
Safety:   Safety data will be listed and summarized a s appropriate.
Pharmacokinetic :  Pharmacokinetic parameter estimates will be evaluated to delineate effects of drug interaction. 
Caffeine, warfarin, dextromethorphan, and midazolam administered in the absence of abemaciclib will represent 
the reference treatments and be analyzed separately.  Each drug administered with abemaciclib will represent the 
test treatments.  Log-transformed C maxand AUC(0 -∞) estimates will be evaluated in a linear mixed -effects analysis 
of variance model with a fixed effect for treatment and a random effect for subject.  The treatment differences will 
be back-transformed to present the ratios of geometric means and the corresponding confidence intervals ( 90% 
CIs).
The t maxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the median difference based on the 
observed medians, 90% CIs, and p -values from the Wilcoxon test will be calculated.
Trough plasma concentrations of abemacicli b will be listed.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 4
Abemaciclib (LY2835219)3.Table of Contents
Effects of Multiple Doses of A bemaciclib on the 
Pharmacokinetics of Cy tochrome P450 (CYP) 1A 2, CYP2C9, 
CYP2D6, and CYP3A  Substrates (Caffeine, Warfarin, 
Dextromethorphan, and Midazolam) in Cancer Patients
Section Page
1. Protocol  I3Y-MC-JPCB(d)  Effects of Mult iple Doses of Abemaciclib on the 
Pharmacokinet ics of Cytochrom e P450 (CYP) 1A2, CYP2C9, CYP2D6, and 
CYP3A Substrates (Caffeine, Warfarin, Dextr omethorphan, and Midazo lam) in 
Cancer Patients ................................................................................................................... 1
2. Synopsis ............................................................................................................................. 2
3. Table of Contents ................................................................................................................ 4
4. Abbre viations and Definit ions........................................................................................... 10
5. Introduction ...................................................................................................................... 14
5.1. Rationale and Justificat ion for the Study ...................................................................... 14
5.2. Object ives.................................................................................................................... 15
5.2.1. Primary Object ive................................................................................................ 15
5.2.2. Secondary  Object ives........................................................................................... 15
5.2.3. Exploratory  Objectives ......................................................................................... 15
5.3. General Introduction to Abemaciclib ............................................................................ 16
5.3.1. Clinical Experience with Abemaciclib .................................................................. 16
5.3.2. Nonclinical Toxico logy........................................................................................ 18
5.4. Rationale for Sel ection of Dose .................................................................................... 18
6. Invest igational Pl an........................................................................................................... 20
6.1. Study  Popul ation.......................................................................................................... 20
6.1.1. Inclusio n Cri teria.................................................................................................20
6.1.2. Exclusio n Cri teria................................................................................................ 21
6.2. Summary  of Study  Design ............................................................................................ 23
6.2.1. Safety Extensio n Phase ........................................................................................ 26
6.2.2. Study  Com pletion and End of Trial ...................................................................... 26
6.2.3. Determinat ion of Sample Size .............................................................................. 26
6.3. Discontinuati ons .......................................................................................................... 27
6.3.1. Discontinuati on of  Patients Inadvertently Enro lled............................................... 27
6.3.2. Discontinuati on of  Patients fro m Study  or Study  Drug ......................................... 28
6.3.3. Patients Lost to Follow -Up................................................................................... 28
6.3.4. Discontinuati on of  Study  Sites............................................................................. 29
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 5
Abemaciclib (LY2835219)6.3.5. Discontinuati on of  the Study ................................................................................ 29
7. Treatment .......................................................................................................................... 30
7.1. Materi als and Supplies .................................................................................................30
7.2. Study  Drug Administration .......................................................................................... 30
7.2.1. Dosing Schedule .................................................................................................. 31
7.2.2. Dose Adjustments ................................................................................................ 32
7.3. Method of Assignment to Treatment ............................................................................ 35
7.4. Blinding ....................................................................................................................... 35
7.5. Concomita nt Therapy ................................................................................................... 35
7.5.1. Interacti ons of Conco mitant Medi cations wi th Abemaciclib .................................35
7.5.2. Interacti ons of Conco mitant Medi cations wi th Drug Cocktail ............................... 36
7.6. Treatment Compliance .................................................................................................37
7.6.1. Evaluable Patients ................................................................................................ 38
8. Safety, Pharm acokinetic, Pharm acodynamic, and Efficacy Data Collect ion....................... 39
8.1. Safety Evaluat ions........................................................................................................ 39
8.1.1. Safety Data Collection and Review ...................................................................... 39
8.1.2. Adverse Events .................................................................................................... 39
8.1.3. Other Safet y Measures ......................................................................................... 43
8.1.4. Safety Moni toring ................................................................................................ 45
8.1.5. Com plaint Handling ............................................................................................. 46
8.2. Sample Collect ion and Test ing..................................................................................... 46
8.2.1. Samples for Study  Qualificat ion and Healt h Monit oring ....................................... 46
8.2.2. Samples for Drug Concentration and Pharmacodynamic Measurements ............... 47
8.2.3. Samples for Eval uation of Renal Funct ion............................................................ 48
8.2.4. Samples for Tailoring Bio markers ........................................................................ 48
8.2.5. CYP Genoty pe Evaluat ion................................................................................... 49
8.3. Efficacy Evaluations .................................................................................................... 49
8.3.1. Prestudy ............................................................................................................... 49
8.3.2. During the Study .................................................................................................. 49
8.3.3. Poststudy Follow-Up............................................................................................ 50
8.4. Procedure/Sampling Co mpliance .................................................................................. 50
9. Data Management Methods ............................................................................................... 51
9.1. Data Qualit y Assurance ................................................................................................ 51
9.2. Data Capture Systems .................................................................................................. 51
9.2.1. Case Report Form ................................................................................................ 51
9.2.2. Ancillary  Data ...................................................................................................... 52
10. Data Analyses ................................................................................................................... 53
10.1. General Considerations ................................................................................................ 53
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 6
Abemaciclib (LY2835219)10.2. Patient Disposi tion....................................................................................................... 53
10.3. Patient Characteri stics.................................................................................................. 53
10.4. Safety Analyses ............................................................................................................ 53
10.5. Pharmacokinet ic Analyses ............................................................................................ 54
10.6. Pharmacodynamic Analyses ......................................................................................... 54
10.7. Efficacy
........................................................................................................................ 55
10.8. Interim Analyses .......................................................................................................... 55
11. Inform ed Consent, Ethi cal Review, and Regulatory Considerat ions.................................. 56
11.1. Inform ed Consent ......................................................................................................... 56
11.2. Ethical Review ............................................................................................................. 56
11.3. Regulatory  Considerat ions........................................................................................... 56
11.3.1. Invest igator Informat ion....................................................................................... 57
11.3.2. Protocol  Signatures .............................................................................................. 57
11.3.3. Final Report Signature ......................................................................................... 57
12. References ........................................................................................................................ 58
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 7
Abemaciclib (LY2835219)List of Tables
Table Page
Table JPCB.7.1. Toxicit y Dose Adjustments and Delays o f Abemaciclib for Study JPCB ........ 33
Table JPCB.7.2. Dose Adjustments for Abemaciclib during Period 3, Period 4, and 
Safety Extensio n............................................................................................ 34
Table JPCB.8.1. Adverse Event and Serious Adverse Reporting Guidelines for Study  
JPCB ............................................................................................................. 43
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 8
Abemaciclib (LY2835219)List of Figures
Figure Page
Figure JPCB.6.1. Study  design. .................................................................................................25
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 9
Abemaciclib (LY2835219)List of Attachments
Attachment Page
Attachm ent 1. Protocol  JPCB Study  Schedule ...................................................................... 60
Attachm ent 2. Protocol  JPCB Clinical Laboratory  Tests ....................................................... 66
Attachm ent 3. Protocol  JPCB Hepat ic Monitoring Tests for Treatment -Emergent 
Abnorm ality.................................................................................................. 68
Attachm ent 4. Protocol  JPCB Reco mmendat ions for Reporting 
SeriousAdverse Events ................................................................................. 69
Attachm ent 5. Protocol  JPCB Eastern Cooperative Onco logyGroup (ECOG) 
Perform ance Status ........................................................................................ 70
Attachm ent 6. Protocol  JPCB Sam pling Summary ................................................................ 71
Attachm ent 7. Protocol  Amendment I3Y -MC-JPCB(d) Summary Effects of Mult iple 
Doses of Abemaciclib on the Pharmacokinet ics of Cytochrome P450 
(CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, 
Warfarin, Dextromethorphan, and Midazo lam) in Cancer Patients ................. 72
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 10
Abemaciclib (LY2835219)4.Abbreviations and Definitions
Term Definition
ABPM ambulatory blood pressure monitoring
AE adverse event:  Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product that does not 
necessarily have a causal relationship with this treatment.  An adverse event 
(AE) can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with 
the use of medicinal (investigational) product, whether or not related to the 
medicinal (investigational) product.
ALT alanine aminotransferase
ASCO American Society of Clinical Oncology 
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC(0 -∞) area under the concentration versus time curve from zero to infinity
AUC(0 -tlast) area under the concentration versus time curve from time zero to time t, where t 
is the last time point with a measurable concentration 
AUC INR area under the INR curve
audit A systematic and independent examination of the study -related activities and 
documents to determine whether the evaluated study -related activities were 
conducted, and the data were recorded, analyzed, and accurately reported 
according to the protocol, applicable standard operating procedures (SOPs), 
good clinical practice (GCP), and the applicable regulatory requirement(s).
CDK cyclin -dependent kinase
CI confidence interval
Cmax maximum observed drug concentration
CNS central nervous system
complaintAny written, electronic, or oral communication that alleges deficiencies related
to the identity, quality, purity, durability, reliability, safety, effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 11
Abemaciclib (LY2835219)confirmation A process used to confirm that laboratory test results meet the quality 
requirements defined by the laboratory generating the data and that Lilly is 
confident that results are accurate.  Confirmation will either occur immediately 
after initial testing or will require that samples be held to be retested at some 
defined time point, depending on the steps required to obtain confirmed results.
CRF/eCRF case report form/electronic case report form:  Sometimes referred to as clinical 
report form, a printed or electronic form for recording study participants’ data 
during a clinical study, as required by the protocol.
CP clinical pharmacologist
CRP clinical research physician
CRS clinical research scientist
CTCAE Common Terminology Criteria for Adverse Events
CYP cytochrome P450
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
end of trial End of trial is the date of the last visit or last scheduled procedure for the last 
patient.
enroll Patients who are enrolled in the trial are those who have been assigned to a 
treatment and have received at least one dose of study treatment. 
enter Patients who are entered in the trial are those who have signed the informed 
consent form directly or thr ough their legally acceptable representatives.
ERB/IRB ethical review board/institutional review board:  A board or committee 
(institutional, regional, or national) composed of medical and nonmedical 
members whose responsibility is to verify that the safe ty, welfare, and human 
rights of the patients participating in a clinical study are protected.
ESA erythroid -stimulating agents 
GCP good clinical practice
IB Investigator’s Brochure
IC50 50% inhibition concentration 
ICF informed consent form
ICH International Conference on Harmonization
informed consent A process by which a patient voluntarily confirms his or her willingness to 
participate in a particular trial, after having been informed of all aspects of the 
trial that are relevant to the patie nt’s decision to participate.  Informed consent 
is documented by means of a written, signed and dated informed consent form.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 12
Abemaciclib (LY2835219)INR internatio nal no rmalized ratio
INR max maximum observed INR response
interim analysis An analy sis of clinical study data that is conducted before the final reporting 
database is authorized for datalock.
investigational 
product (IP)A pharmaceutical form of an active substance or placebo being tested or used as 
a reference in a clinical trial .  Investigational product includes a product with a 
marketing authorization w hen used or assembled (formulated or packaged) in a 
way different f rom the authorized form, used for an unauthorized indication or 
used to gain further information about the authorized form
investigator A person re sponsible for the conduct of the clinical study at a study site.  If a 
study is conducted by a team of individuals at a study site, the investigator is the 
responsible leader of the team and may be called the principal investigator.
KIM-1 kidney injury mo lecule -1 
MRI magnetic resonance imaging
NCI Natio nal Cancer Institute
NGAL neutrophil gelatinase -associated lipocalin 
NSCLC non-small -cell lung cancer 
open -label A study  in which there are no restrictions on knowledge of treatment allocation, 
therefore the investigator and the study participants are aware of the drug 
therapy  received during the study.
patient A subject with a defined disease.
PD pharmacodynamic(s) 
PK pharmacokinetic(s)
PRO patient reported outcomes 
Q12H every 12 hours 
RECIST Response Evaluation Criteria in Solid Tumors
re-screen to screen a patient who was previously declared a screen failure for the same 
study
SAE serious adverse event
screen The act of determining if an individual meets minimum requirements to beco me 
part of a pool of potential candidates for participation in a clinical trial.  In this 
study, screening involves invasive or diagnostic procedures and/or tests (for 
example, blood draws).  For this type of screening, informed consent for these 
screening procedures and/or tests shall be obtained; this consent may be 
separate from obtaining consent for the study.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 13
Abemaciclib (LY2835219)screen failure A patient who does not meet one or more criteria required for participation in a 
trial
sponsor The party who takes responsibilit y for the initiatio n, management and/or 
financing of a clinical study.
SUSAR suspected unexpected serious adverse reactions
t1/2 half-life associated with the terminal rate constant
TEAE treatment -emergent adverse event
tmax time of maximal plasma concentration
TPO third -party organization
ULN upper limit of normal
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 14
Abemaciclib (LY2835219)Effects of Multiple Doses of A bemaciclib on the 
Pharmacokinetics of Cy tochrome P450 (CYP) 1A 2, CYP2C9, 
CYP2D6, and CYP3A  Substrates (Caffeine, Warfarin, 
Dextromethorphan, and Midazolam) in Cancer Patients
5.Introduction
5.1. Rationale and Justification for the S tudy
Study  JPCB is a Phase 1 study  designed to invest igate the effect of mult iple doses of abemaciclib 
on the pharmacokinet ics (PK) of cy tochrom e P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A 
substrates in patients with advanced and/or metastatic cancer.
Abema ciclib is an orally administered small mo lecul e that i s a potent and selective dual inhibitor 
of the cy clin-dependent kinases (CDKs) 4 and 6.  The goal of inhibit ing CDK4 and CDK6 is to 
prevent cell cycle progression through the G1 restrict ion point, thus arresting tumor growth.
Abemaciclib at doses of 200 mg every 12 hours (Q12H) is being developed for the treatment of 
advanced cancer, including metastatic breast cancer and Stage IV non -small-cell lung cancer.
Abemaciclib has been administered orally on Da ys 1 through 28 of a 28- day cycle.  In Study  
JPBA, the maximum tolerated dose for humans when administered as a single agent was200 m g 
Q12H.  Based upon a higher incidence of Grade 3 diarrhea when abemaciclib 200 mg Q12H was 
administered in combinat ion with nonsteroi dal aromatase inhibitors, the dose being explored in 
combinat ion with nonsteroi dal arom atase inhibitors in Study  JPBM i s 150 m g Q12H.
In vitro in human liver microsomes, abemaciclib and its major circulat ing metabo lites 
LSN2839567 (M2) and LSN3 106726 (M20) did not inhibit direct ly or in a time -dependent 
manner the catalyt ic act ivities of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, 
and CYP3A at clinically relevant concentrations.  Furthermore, abemaciclib and its metabo lites 
did not induce t he catalyt ic act ivities of CYP1A2, CYP2B6 ,and CYP3A.  Thus, collect ively, 
these in vitro data suggest that abemaciclib and its metabo lites do not interact direct ly wit h the 
above CYPs, and that drug interactions are unlikely due to CYP inhibit ion or induc tion when 
abemaciclib is coadministered with substrate drugs of the above CYPs.
Although abemaciclib and its major metabo lites did not inhibit any of the CYPs direct ly in 
human liver microso mes, down regulat ion of mRNA of CYPs, including CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, and CYP3A by abemaciclib and/or its major circulating 
metabo lites LSN2839567 (M2) and LSN3106726 (M20), was observed at clinically relevant 
concentrations in cultured human hepatocy tes.  The observed mRNA down regulat ion was 
>50%, con centrati on dependent and not due to toxicit y to cells.  The mechanism o f this down 
regul ation and its clinical relevance (in vitro to in vivo correlat ion) are present ly not understood.  
Thus, in the absence of addit ional in vitro data there i s a potenti al for abemaciclib and its major 
metabo lites to interact wi th substrate drugs of the above CYPs when coadministered (EMA 
Guidance 2012; PMDA Draft Guidance 2013).
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 15
Abemaciclib (LY2835219)Under this circumstance, regulatory  agencies recommend conduct ing a clinical drug interaction 
study using a cocktail approach (EMA Guideline 2012; PMDA Draft Guideline 2013).  Drugs 
used in such a cocktail should be select ive for the specific CYP enzymes, should not interact 
with each other, and ultimately  shoul d be safe when administered.  One such cocktail is a 
modified Coopertown 5 + 1 cocktail which includes caffeine (CYP1A2), warfarin (CYP2C9), 
omeprazo le (CYP2C19), dextromethorphan (CYP2D6) and midazo lam (CYP3A), and has been 
administered to patients with advanced cancers (excluding primary live r tum ors) (Goh et al. 
2010; Ma et al. 2006 ).  In this study , based on the in vitro data, only  caffeine, warfarin, 
dextrom ethorphan, and midazo lam will  be included in the cocktail.  
Secondary  and exploratory  objectives of this study are to collect closely -monitored data on bl ood 
pressure, diarrhea, and renal funct ionthat will further characterize the safet y and tol erabili ty of 
abemaciclib in patients.
The sponsor, monitor, and invest igators will perform this study in compliance with the protocol, 
good clin ical pract ice (GCP) and Internat ional Conference on Harmonizat ion (ICH) guidelines, 
and applicable regulatory  requi rements.
5.2. Objectives
5.2.1. Primary Objective
The primary  object ive of this study  is to assess the effect of abemaciclib on the PK of caffeine 
(CYP1A2 substrate), warfarin (CYP2C9 substrate), dextromethorphan (CYP2D6 substrate), and 
midazo lam (CYP3A substrate) in cancer patients after mult iple oral  doses of abemaciclib.
5.2.2. Secondary Objectives
The secondary  objectives of this study  are:
to character ize the tolerabilit y of coadministration of abemaciclib with caffeine, warfarin, 
dextrom ethorphan, and midazo lam following mul tiple doses of abemaciclib in cancer 
patients.
to assess the effect of abemaciclib on blood pressure and pulse rate fo llowing m ultiple 
doses of abemaciclib in cancer patients.
5.2.3. Exploratory Objective s
The exploratory  objectives of this study  are:
todetermine the effect of abemaciclib on the pharmacodynamics (PD) of a single dose of 
warfarin as measured by internat ional normalized ratio (INR).
to assess the effect of abemaciclib on markers of renal funct ion, including 
creatinine, cystatin -C, ki dney  injury  molecule -1 (KIM -1), and neutrophil 
gelatinase -associ ated lipocalin (NGAL).
to characterize bowel habits via a patient diary  and a stool  assessment tool (Bristol Stool 
Chart). 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 16
Abemaciclib (LY2835219)to characterize diarrhea experienced via pat ient reported outcome data bas ed on selected 
individual items fro m exist ing patient reported outcomes (PRO) scales (FACIT -D) as 
well as custom -generated PRO items.
5.3. General Introduction to Abemaciclib
Abemaciclib is a select ive and potent small mo lecul e CDK4 and CDK6 dual inhibitor with broad 
antitumor activit y in preclinical pharmaco logy models, acceptable physical and PK properties, 
and an acceptable toxicit y profile in nonclinical species.  This co mpound demonstrates 
significant inhibit ion of tumor growth as monotherapy  in multiple hu man xenograft models 
including models for: colorectal cancer, glio blastoma mult iform e, acute myelo id leukemia, 
melano ma, mantle cell lympho ma, and non -small -cell lung cancer (NSCLC).  
More informat ion about the known and expected benefits, risks ,and reas onably  anticipated 
adverse events (AEs) may be found in the Invest igator’s Brochure (IB).  Information on AEs 
expected to be related to the invest igational product may be found in Sect ion 7 (Development 
Core Safety  Information) of the IB.  Informat ion on s erious adverse events (SAEs) expected in 
the study  popul ation independent of drug exposure and that will be assessed by the sponsor in 
aggregate, periodically during the course of the study , may be found in Sect ion 6 (Effects in 
Hum ans) of  the IB.
5.3.1. Clinical Experience with Abemaciclib
Abemaciclib has been evaluated in mult iple Phase 1 clinical pharmaco logy studi es, incl uding 
4studi es co mpleted in healt hy subjects and 2 studies completed in cancer patients.  Three 
Phase 1 studi es are ongoing in healthy subje cts and several Phase 1 studies are underway in 
cancer patients.
Phase 2 studies are ongoing in metastatic breast cancer and mant le cell lympho ma pat ients and 
Phase 3 studies are ongoing in pat ients with metastati c breast cancer and in patients with 
Stage IV NSCLC .
5.3.1.1. Pharmacokinetics of Abemaciclib and Its Major Metabolites
The time course of abemaciclib concentration in plasma shows a median t ime of maximum 
observed drug concentration (t max) ranging fro m 4 to 6 hours postdose.  Abemaciclib has a 
half-life as sociated wi th the terminal rate constant (t 1/2) ranging fro m 17 to 38 hours and showed 
no dose dependent change in clearance.  The time to steady  state following mult iple Q12H doses 
of abemaciclib is approximately  5 days.
Based on in vitro data, the major human circulat ing metabo lites LSN3106726 (M20) and 
LSN2839567 (M2) are active with potency  similar to abemaciclib.  Thet1/2 was longer for 
metabo lites than that of abemaciclib, with mean values of 36 and 32 hours for M2 and M20, 
respectively .  
Addit ionalinformation on the PK properties of abemaciclib, including the PK at steady  state 
after repeated abemaciclib administration, is available in the IB.  The majorit y of abemaciclib is 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 17
Abemaciclib (LY2835219)eliminated in feces (81%) with approximately  3% of  the dose eliminated in urine.  Abemaciclib 
is extensively  metabo lized primarily via CYP3A.
5.3.1.2. Clinical Activity Data
Abemaciclib has demonstrated evidence o f clinical activit y in several tumor ty pes.  In Study  
JPBA, r adiographic responses were achieved in previously treated patient s with breast cancer, 
NSCLC, and melano ma.  For hormone receptor -posit ive breast cancer, overall response rate was 
31% (11/36 patients) and disease control rate was 81% (29/36 patients).
5.3.1.3. Clinical Safety Data
Safety data for 352 patients treated with abemaciclib in 6 studies show that the m ost comm on 
treatm ent-emergent AEs (TEAEs; ≥10%) possibly  related to study  drug for pati ents receiving 
abemaciclib eit her as a single agent, with endocrine therapy , or wi th chemotherapy, are di arrhea 
(64.2%), nausea (44.3%), fat igue (39.8%), neutropenia (27.0%), vomit ing (24.1%), 
thrombocy topenia (21.3%), l eukopenia (21.0%), anemia (17.6%), decreased appetite (17.6%), 
and increased blood creatinine (14.5%).  The majo rity of deaths reported for patients in the 
studi es wi th available safet y data were due to study  disease.
Preliminary safet y data from  Study  JPBH, a Phase 1b study  evaluat ing the safet y and tol erabili ty 
of abemaciclib in co mbination wit h endocrine therapies (includin g anastrozol e) in patients with 
HR+, HER2- mBC, have shown an AEprofile for abemaciclib administered at 200 mg every 
12hours in co mbination wit h endocrine therapies that is consistent with the profile observed in 
the Study  JPBA mBC single agent cohort.  However, at the 200- mg dose, the incidence of 
treatm ent-emergent Grade 3 diarrhea was greater in co mbination wit h endocrine therapies than 
when abemaciclib was administered alone (25.7% and 13.6%, respectively).  Although diarrhea 
occurred in 62.5% of pati ents in the dose -confirmation phase of Study JPBA (57.1% of patients 
at the 150 -mg dose and 68.0% of patients at the 200 -mg dose), this diarrhea was most ly Grade 1 
or Grade 2 and was manageable with standard ant i-diarrheal agents.  There have been no patie nt 
discontinuat ions due to diarrhea.
In one study , a total  of 16 pati ents were taking warfarin while also taking abemaciclib: one 
patient each at abemaciclib doses of 100 mg Q12H and 225 mg daily, 6 patients at 200 m g 
Q12H, and 8 patients at 150 mg Q12H.  Two patients in this group of 16 patients had an AE
potenti ally related to increased warfarin exposure that could potentially  occur if CYP2C9 activit y 
was decreased.  One pat ient had Grade 1 epistaxis and an increased INR on Day 28 of the study 
while takin g a dose of 200 mg abemaciclib Q12H.  One patient had a Grade 3 upper 
gastrointestinal hemorrhage on Day  179 of the study  while taking a dose of 150 mg abemaciclib 
Q12H.Increases in serum creat inine of approximately 20% to 40% above baseline have been 
observed across healt hy subject and cancer patient studies.  In vitro preliminary data from 
transporter inhibit ion studi es have shown that abemaciclib and its major metabo lites inhibi t 
multiple drug and toxin extrusion transporter 1.  Thus, the observed transi ent increases in serum 
creatinine are likely to be due to inhibit ion of tubular secretion of creatinine by th istransporter 
without clinically meaningful alterat ions in renal funct ion (Schützer et al. 2010 ;Imamura et al . 
2011; Lepist et al. 2014).
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 18
Abemaciclib (LY2835219)Changes in blood pressure and pulse rates have been seen in studies wit h abemaciclib.  In 
healt hy subjects enro lled in Study  JPBG, sm all decreases in mean blood pressure and increases 
in mean pul se rates were observed up to 24 hours following dosing with abemacic lib in each 
study  period.  Maximal  mean changes were up to -5.0 mmHg for sy stolic blood pressure 
and -4.3mmHg for diastolic blood pressure, and up to 4.3 bpm increases in pulse rate.  In cancer 
patients enrolled in Study  JPBA, decreases in blood pressure were observed fo llowing dosing 
with abemaciclib on Days 8, 15, 22, and 28 of Cycle 1 and Day 28 of Cycles 2 through 6.  
Maximal median changes were up to -6 mmHg for diastolic blood pressure (Cycle 1 Day 28) and 
-5 mmHg for sy stolic bl ood pressure (Cy cle 1 Day 22).  Decreases fro m baseline in pulse rate 
were observed on Days 15 and 22 of Cycle 1, as well as on Day 28 of Cycles 3 through 6, with 
maximal median change in pulse rate being -6.0 bpm (Cycle 6 Day 28).  To date there is no 
evidence of an effect of abemaciclib on QT interval.
5.3.2. Nonclinical Toxicology
To support human clinical studies, the toxicit y profile of abemaciclib has been effect ively 
characterized in rat and dog through a package of repeat -dose toxico logy, safety  pharmacol ogy, 
and genet ic toxic ology studi es.  These studies demonstrate an acceptable safet y profile wi th 
toxicities that are generally  considered to be m onitorabl e and reversible.  
The nonclinical toxico logy studies consisted of 28 -day repeat -dose studies in rats at doses of 10, 
30, and 50 mg/kg/day (60, 180, and 300 mg/m 2, respect ively) and in dogs at doses of 1, 3, and 
10mg/kg/day (20, 60, and 200 mg/m 2, respect ively).  Dose -responsive hematotoxicit y, indicated 
by cytopenias and bone m arrow hy pocellularit y, and gastrointestinal injury  were the m ost 
prominent adverse effects observed in both rats and dogs.  In addition, effects on male 
reproducti ve tract were also observed.  These changes were generally consistent with 
antiproliferat ive effects and demo nstrated parti al or com plete reversibilit y within the 28 -day 
recovery  period in both speci es.  Im portantly, the toxi cities associ ated wi th abemaciclib in 
preclinical studies have generally been observed wit h multiple or repeated dosing, consistent 
with its cell cycle -related m echanism of act ion.  
No im portant com pound- related findings were observed in safet y pharmaco logy studies of the 
cardi ovascular system ,respiratory  system , or central  nervous system  (CNS) in preclinical  studi es.  
Although the 50% inhibit ion concentration (IC 50) was not precisely determined in an in vitro 
model (IC 50>1.65 M), no QTc prolongat ion was observed in dogs at doses up to 10 mg/kg; 
therefore, the risk for QTc prolongat ion to occur in humans is considered low .  
For m ore details about the results of the nonclinical toxico logy studi es, please refer to 
Secti on5.2.1 of the IB.
5.4. Rationale for Selection of Dose
A drug cocktail containi ng oral  doses of 2 mg/kg caffeine, 10 mg warfarin, 40 mg omeprazo le, 
30 m g dextrom ethorphan, and 0.075 mg/kg midazolam has been studied previously (Ma et al. 
2006), wi th no safet y concerns raised.  Another study  evaluat ing this cocktail of drugs in pat ients 
with advanced cancer also had no safet y concerns rai sed (Goh et al . 2010).  Therefore, the drug 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 19
Abemaciclib (LY2835219)cocktail proposed in the current study , which contains 100 mg caffeine, 10 mg warfarin, 30 mg 
dextrom ethorphan, and 0.2 mg midazo lam, is expected to be safe a nd well tolerated. 
Abemaciclib 
A dose of 200 mg Q12H was selected for this study and is supported by  the safet y data fro m a 
cancer patient study in which the highest dose explored was 275 mg Q12H, and the maximum 
tolerated dose was i dentified as 200 mg Q 12H based on dose -limit ing toxicit y of Grade 3 fatigue 
observed in 2 of 3 patients at 275 mg Q12H.  Likewise, the 200 -mg dose is supported by safet y 
data from  heal thy subject studi es.  The available nonclinical toxicology  data al so supports the 
dose sel ected for this study .  The 200 -mg dose is also being invest igated in the Phase 2 and 
Phase 3 single agent studies of abemaciclib in cancer patients.
At the conclusio n of the drug interaction portion of the study , patients m ay cont inue to receive 
abemaciclib t hrough Cycle 2 at the invest igator’s discretion.  In the safet y extensio n phase, 
patients will  receive abemaciclib at a dose of 200 mg Q12H (or modified as applicable) on a 
28-day cycle unt il discont inuat ion criteria are m et.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 20
Abemaciclib (LY2835219)6.Investigational Plan
6.1. Study Pop ulation
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
re-screened.  Individuals may be re -screened up to 1 time.  Prospective approval o f protocol  
deviat ions to recruit ment and enro llment criteria, also kn own as protocol waivers or exempt ions, 
are not permitted.
6.1.1. Inclusion Criteria
Patients m ay be included in the study  if they  meet all  of the f ollowing cri teria during screening 
prior to enrollment .
[1] Have histological or cy tological evidence of a diagnosis of cancer that i s 
advanced and/or metastatic.  The patient must be, in the judgment of the 
investigator, an appropriate candidate for experimental therapy  after available 
standard therapies have failed to provide clinical benefit for their disease.
[2] Are 18 years of age.
[3] Have given written informed consent prior to any  study -specific procedures .
[4] Have adequate organ funct ion, including:
Hem atologic:  Absol ute neutrophil count 1.5x 10 9/L, pl atelets 100 x 
109/L, and hemoglo bin 8g/dL.  Patients may receive erythrocyte 
transfusio ns to achieve this hemoglobin level at the discret ion of the 
investigator.  Init ial treatm ent m ust not begin unt il 1 day  after the 
erythrocyte transfusio n.  
Hepati c:  Directbilirubin 1.5 times upper limits of norm al (ULN), 
alanine aminotransferase (ALT), and aspartate aminotransferase (AST) 
2.5times ULN.  PT or INR 1.2 times ULN and PTT 1.2 times ULN .
Renal:  Serum creat inine no greater than ULN.
[5] Have other clinical laboratory  test resul ts wi thin norm al reference range or 
resul ts wi th acceptable deviat ions that are judged to be not clinically 
significant by  the invest igator .
[6] Have a performance status of 2 on the Eastern Cooperative Onco logy Group 
(ECOG) scal e (refer to Attachment 5).
[7] Have discontinued all previous therapies for cancer (including chemotherapy , 
radiotherapy , immunotherapy , cancer -related hormone therapy , and 
investigat ionaltherapy ) for at l east 21 day s for myel osuppressive agents or 
14days for nonmyelo suppressive agents prior to receiving study  drug and 
have recovered fro m the acute effects of therapy  (treatm ent rel ated toxi city 
resolved to baseline), except for residual a lopecia.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 21
Abemaciclib (LY2835219)At the di screti on of  the invest igator, hormone refractory prostate cancer 
patients who are stable on gonadotropin -releasing horm one agonist therapy  
may have that treatment continued while they  are enrolled in Study  JPCB.   
Other hormonal treatments used for non -cancer indicat ions (or cancer -induced 
indicat ions, for example megestrol acetate to treat anorexia) may also be 
allowed at the discret ion of the invest igato r.
Exemptions will be permitted on a case -by-case basis after pri or approval  by 
the Lilly clinical  research physician ( CRP )/clinical pharm acologist ( CP)or 
designee if the investigator believes the patient’s risk of recurrence and death 
is very low. Curatively treated nonmelano ma skin cancer or in situ carcino ma 
of any ori gin is all owed.
[8] Are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures.
[9] If male or female wit h reproductive potential, agree to use medically approved 
contraceptive precaut ions during the trial and for 3 months fo llowing the l ast 
dose of study  drug.  In addit ion, male pat ients must not donate sperm during 
the trial and for 3 m onths fo llowing the l ast dose of study  drug.
[10] If female with child bearing potential, must have a negat ive serum pregnancy  
test wi thin 3 days of the first dose of study  drug.
[11] Have an est imated life expectancy, in the judgment of the investigator, that 
will permit the patient to complete the drug interaction phase and at least 
1cycle of abemaciclib (if the pat ient were to participate in the safet y 
extensio n).
[12] Are able to swallow capsules or tablets.
6.1.2. Exclusion Criteria
Potenti al study  patients m ay not be included in the study  if any of the fo llowing apply during 
screening.
[13] Have received treatment within 28 d ays o f the init ial dose of study drug with 
an invest igational product (non-cancer -related therapi es) or non -approved use 
of a drug or device (other than the study  drug used in this study ) or are 
concurrent ly enro lled in any other ty pe of m edical  research j udged not to be 
scientifically or medically co mpatible wit h this study .
[14] Have a personal history  of any of the fo llowing condi tions:  presyncope or 
syncope of either unexplained or cardiovascular et iology , ventricular 
arrhy thmia (incl uding but not limi ted to ventri cular tachycardia and 
ventri cular fibrillat ion), or sudden cardiac arrest .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 22
Abemaciclib (LY2835219)[15] Have known act ive uncontrolled or symptomat ic CNS metastases,
carcino matous m eningi tis, or l eptom eningeal  disease as indicated by  clinical  
symptoms, cerebral edema, and/or progressive growth. Patients with a history  
of CNS m etastases or cord compressio n are eligible if they  have been 
definit ively treated (eg, radiotherapy ,stereotactic surgery) and are clinically 
stable off ant iconvulsants and steroi ds for at least 4 weeks before 
rando mizat ion.
[16] Have a primary liver tumor .
[17] Have a clinically  significant abnormal electrocardiogram  (ECG )with any  (but 
not limited to) the fo llowing findings:  persistent and significant ventricular 
arrhy thmia, evi dence of acute my ocardial  ischemia, or QTc prolongat ion 
(defined as QT interval corrected for heart rate using Bazett’s formula 
>470 msec).
[18] Have preexist ing medical condit ions that, in the judgment of the investigator, 
woul d precl ude parti cipat ion in this study  (for example, history  of major 
surgi cal resect ion involving the stomach or small bowel, nausea, vo miting, 
diarrhea ,or malabsorpti on syndromes).
[19] Have lympho ma or leukemia.
[20] Have any history  of receiving an autologous or allogeneic stem -cell or bone 
marrow transplant
[21] For Periods 1 and 2:
Require treatm ent wi th inducers or inhibitors of CYP1A2, CYP2C9, 
CYP2D6, and CYP3A wit hin 14 days before the first dose of study  
drug through the end of Period 2
Require treatm ent wi th substrat e drugs of CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, and CYP3A with narrow therapeutic 
indices, at the discret ion of the investigator following discussio n and 
agreem ent wi th the Lilly  CRP/CP or desi gnee.
Note: Following Period 2 and during the remainder of t he study:
Inducers and inhibitors of CYP3A, as well substrate drugs of CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, and CYP3A with narrow therapeutic indices should be 
avoided ( see Section 7.5Concomitant Therapy ).
[22] Requi re cont inued treatment with other drugs that are contraindicated with 
caffeine, warfarin, dextromethorphan, or midazo lam.
[23] Have a known hypersensit ivity to caffeine, warfarin, dextrom ethorphan, or 
midazo lam.
[24] Are pregnant or lactating females.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 23
Abemaciclib (LY2835219)[25] Have act ive bacteri al, fungal , and/or known si gnificant viral infect ion (for 
example, human immunodeficiency  virus ant ibodies, hepat itis B surface 
antigen, or hepatit is C ant ibodi es).  Screening of these infect ions are not 
requi red for enrollment.
[26] History  or presence of significant bleeding disorders that is, hematemesis, 
melanena, other known gastrointest inal bleeding (wi thin the last 3 -6 months) 
with significant ri sk of recurrence, severe or recurrent epistaxis, hemoptysis, 
clinically overt hematuria, or intracranial hemorrhage.
[27] Have a history  of major head traum a (wi th loss of consci ousness) wi thin the 
past y ear or minor head trauma (without loss of consciousness) with in the l ast 
3 months pri or to screening .
6.2. Summary of Study Design
This will be an open -label, 4-period, fixed -sequence study , followed by a safet y extensio n phase, 
in patients with advanced and/or metastatic cancer.
The drug cocktail o f 100 m g caffeine, 10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg 
midazo lam will be administered orally as a single dose on 2 occasions: Day 1 in Peri od 1, and in 
combinat ion with abemaciclib on Day  8 of Period 2, after 7 day s of 200 m g abemaciclib Q12H 
dosing.  After complet ing Period 2, patients will continue to receive abemaciclib at a dose of 
200mg Q12H (or a modified dose) through the end of Periods 3 and 4, in 28 -day cycles, and 
then may cont inue in a safet y extensio n phase un til discont inuat ion criteria are m et.  Pati ents 
who do not complete dosing and PK sampling through Period 2 may be replaced .
Patients will  be provi ded wi th an electronic diary  from the baseline visit through the end of 
Cycle 2 to record the time and date o f abemaciclib administration, ant i-diarrhea medicat ions 
taken, and bowel habits and any changes.
The study  design i s illustrated in Figure JPCB. 6.1.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 24
Abemaciclib (LY2835219)Period 1
Patients will  report to the study  site wi thin 7 days prior to the first dose of drug cocktail dosing 
for baseline safety  assessments, init ial diary  training, and bowel habit assessment, and PRO scale 
completion.  Patients will also be fitted with an ambulatory  blood pressure m onitor (ABPM) 
device for a 12 -hour acclimat ion peri od between Days -7 to -2.  Patients will begin co llecting 
daily  baseline diary  assessments for bowel habits following the baseline visit.  Patients will 
report to the study  siteon Day  -2 or Day  -1 prior to procedures and dosing on Day 1 for 24 -hour 
ABPM m easurements ,which will serve as the baseline.  Patients will then report to the study site 
prior to dosing on Day  1.  On Day  1, pati ents will  receive the drug cocktail, with si ngle oral  
doses of 100 mg caffeine, 10 mg warfarin, 30 mg dextromethorphan, and 0.2 mg midazo lam 
coadministered at the same time.  Serial blood samples will be co llected to determine the 
concentrations of caffeine, S -warfarin, dextromethorphan, and midazo lam.  Pati ents will  be 
present at the study  site for at l east 12 hours after dosing, and then return to the study  site on an 
outpati ent basis for the collection of PK and/or PD samples.
Period 2
Period 2 will begin no earlier than 7 days after the cocktail dose in Peri od 1.  Pri or to 
abemaciclib dosing, safet y assessments will be collected.   Patients will receive the first dose of 
200 m g abemaciclib at the study  site and then will  be released wit h a sufficient supply  of 
abemaciclib for 8 days taken Q12H.  Pa tients will report to the study  site between Days 5 to 7 
and will be fitted with an ABPM device for a 24 -hour measurement after mult iple doses of 
abemaciclib.  Patients will report to the study  site on Day  8 and will be coadministered 
abemaciclib and the d rug cocktail in the morning.  Serial blood samples will be co llected after 
dosing on Day 8 to determine the concentrations of caffeine, S -warfarin, dextromethorphan, and 
midazo lam.  Bl ood sam ples will  also be collected for the measurement of trough concent rations 
of abemaciclib.  Patients will be present at the study  site for at l east 12 hours after dosing wit h 
the drug cocktail, and then released with a sufficient supply o f abemaciclib.  Patients will return 
to the study  site on an outpati ent basis for the collection of PK and/or PD samples.
Period 3 and 4
After complet ing Period 2, it is anticipated that patients will cont inue 200 mg abemaciclib Q12H 
during Peri ods 3 and 4 for assessment of bowel changes .This will co mplete Cy cles 1 and 2 of 
abemaciclib treatment, as depicted in Figure JPCB. 6.1.
Safety monitoring will  be conducted throughout the ent ire study  durati on.
Refer to Attachment 1 for the Study  Schedule.
I3Y-MC-JPCB(d) Phase 1 Oncology P rotocol Page 25
Abemaciclib (LY2835219)
Abbreviations:  ABPM = ambulatory blood pressure monitoring; PK = pharmacokinetics; PRO = patient reported outcomes; Q12H = e very 12 hours.
ABPM will be performed at following times: 12 -hour acclimation period between Days -7 to -2 in Period 1, 24 -hour perio d between Day -2 and dosing on Day 1 
in Period 1, and 24 -hour period between Days 5 to 8 in Period 2.
Figure JPCB. 6.1. Study design.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 26
Abemaciclib (LY2835219)6.2.1. Safety Extension Phase
Patients who parti cipate in the safet y extensio n phase of the study  will receive an abemaciclib 
dose of 200 mg Q12H (or modified dose as applicable) on a 28- day cycle until discont inuat ion 
criteria are met (eg, disease progression, death, or unacceptable t oxicity (Secti on 6.3).If 
interrupti ons in dosing are required for significant periods of time (> 14 days) continuat ion of 
treatm ent wi th abemaciclib may  be consi dered if fel t to be in the best interest of the patient’s 
care and upon discussio n with the m edical mo nitor. Tumor re -staging may be allowed and will 
be docum ented when necessary .
Invest igators m ay perform other standard procedures and tests needed to treat and evaluate 
patients; however, Lilly will not routinely  collect the results of these assessments.  Any AEs 
discovered during the safet y extensio n phase will be collected.
The patient’s pa rticipat ion in the safet y extensi on peri od will be completed after therapy  is 
discontinued.  A fo llow-up assessment should occur approximately  10 days after the l ast 
abemaciclib dose is given.  If a patient is required to begin a new treatment or invest igational 
product, the fo llow-up assessment may  take pl ace sooner fo llowing discont inuat ion of study  
treatm ent.
While efficacy  is not a primary  object ive of Study JPCB, responses will be fo llowed and 
recorded by  the Response Evaluat ion Cri teria in Solid Tum ors (RECIST) criteria for solid 
tumors.  Response data will be collected and tabulated.
6.2.2. Study Completion and End of Trial
This study  will be considered com plete (that i s, the sci entific evaluation will be co mplete [study  
completion]) after all pat ients have completed treatment and their safet y summary visit.  “End of 
trial” refers to the date of the last visit or last scheduled procedure for the last patient.
The end o f trial occurs after study  com pletion and after the last patient has discont inued study  
treatment and com pleted any  applicable continued access follow -up.
6.2.3. Determination of Sample Size
Up to 48 pati ents may  be enrolled in order that 22 patients complete Periods 1 and 2.
Caffeine
For caffeine area under the concentration time curve ( AUC ), the intra -subject variabilit y 
(coefficient of variat ion) was es timated to be 21.0% (Blanchard and Sawers 1983); 22 patients 
will provide a precision o f 0.13 on the l og scal ewith 90% power. 
Warfarin
For warfarin AUC, the intra -subject variabilit y (coefficient of v ariation) was est imated to be 7% 
(Steinijans et al. 1995); 22 patients will provide a precisio n of 0.04, with 90% power, which 
corresponds to 4.4% on the log scale. For warfarin Cmax, the intra -subject variabilit y was 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 27
Abemaciclib (LY2835219)estimated to be 8% (Steinijans et al.1995); 22 patients will provide a precision o f 5.0% on the 
log scale with 90% power.
Dextromethorphan 
For dextrom ethorphan AUC, the intra -subject variabilit y (coefficient of variat ion) was est imated 
to be 33.7% (derived fro m a previous study ); 22 pati ents will provide a precisio n of 0.20, with 
90% power, which corresponds to 22.4% on the log scale. For dextrom ethorphan C max, the 
intra-subject variabilit y was est imated to be 32.1% (derived fro m a previous study ); 22 patients 
will provide a precision o f 21.3% on the l og scal ewith 90% power .
Midazolam
For midazo lam AUC, the intra -subject variabilit y (coefficient of variat ion) was est imated to be 
16.1% (derived fro m a previous study ); 22 pati ents will provide a precisio n of 0.10, with 90% 
power, which corres ponds to 10.4% on the log scale. For midazo lam Cmax, the intra -subject 
variabilit y was est imated to be 26.4% (derived from a previous study); 22 patients will provide a 
preci sion of 17.3% on the l og scale with 90% power .
ABPM
Using an intra -subject standa rd error of 9.48 mmHg in systo lic blood pressure fro m Study  JPBA, 
a sam ple size of 22 com pleted patients will provide more than 90% coverage probabilit y that the 
half-width of the 90% confidence interval (CI) for the difference in means will be approximate ly 
6 mmHg. The intra -subject standard error of diastolic blood pressure was est imated to be 
6.78 mmHg and will provide more than 90% coverage probabilit y that the half -width of the 90% 
CI is in difference of means to be 4.3 mmHg.
6.3. Discontinuations
The reas on for and date of discont inuat ion will be collected for all pat ients.  The date of 
discontinuat ion (for any  of the above reasons) from study  treatm ent is to be reported on the 
electroni c case report form (eCRF).  Patients who discontinue will have fo llow-up procedures 
perform ed as shown in the Study  Schedule ( Attachment 1 ).
If a patient withdraws informed consent, he or she must not be contacted unless he or she has 
explicit ly provided permissio n and consent.  Lilly may cont inue to use previously co llected 
medical research data prior to the withdrawal consistent with the original authorizat ion.
6.3.1. Discontinuation of Patients Inadvertently Enrolled
The cri teria for enrollment m ust be fo llowed explici tly.  If the invest igator site ident ifies a patient 
who did not me et enrollment criteria and who was inadvertent ly enro lled, the sponsor must be 
notified.  If the sponsor ident ifies a pat ient who did not meet enrollment criteria and who was 
inadvertent ly enro lled, the invest igator site will be notified. A discussio n must occur between 
the sponsor CRP and the invest igator to determine whether the patient may cont inue in the study , 
with or wi thout invest igational product.  Inadvertent ly enro lled pat ients may be maintained in the 
study  and on investi gational product when th e Lilly  CRP agrees wi th the invest igator that it is 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 28
Abemaciclib (LY2835219)medically appropriate for that patient. The patient may not continue in the study  with or wi thout 
investigat ional product if the Lilly  CRP does not agree wi th the invest igator’s determinat ion that 
it is medically appropriate for the patient to continue. The invest igator must obtain documented 
approval  from the Lilly  CRP to all ow the inadvertent ly enro lled pat ient to conti nue in the study  
with or wi thout invest igational product.
6.3.2. Discontinuation of Patient s from Study or Study Drug 
Patients who are di scont inued fro m the study  drug early  will have fo llow-up procedures 
perform ed as shown in the Study  Schedule ( Attachment 1 ).
In addit ion, pati ents will  be discont inued fro m the study  drug and/or from the study  in the 
following circumstances:
Enrollment in any other clinical trial invo lving an investigational product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study .
Invest igator/Physician Decisio n
othe invest igator/physician decides that the patient should be discontinued from the 
study  or study drug(s) .
othe pati ent, f or any  reaso n, requires treatment with another therapeutic agent that 
has been demonstrated to be effect ive for treatm ent of the study  indicat ion, 
discontinuat ion from the study  drug(s) occurs prior to introduction of the other 
agent .
Patient Deci sion
othe pati ent requ ests to be discont inued fro m the study  or study drug .
Sponsor Decisio n
oLilly stops the study  or stops the patient’s participation in the study  for medical, 
safet y, regul atory , or other reasons consistent with applicable laws, regulat ions, 
and GCP .
The pati ent has evidence of progressive disease.
The patient experiences unacceptable toxicit y.
The patient is nonco mpliant with study  procedures and/or treatment (Section 7.6).
6.3.3. Patients Lost to Follow -Up
A pat ient would be considered lost to fo llow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by  the study  site.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 29
Abemaciclib (LY2835219)6.3.4. Discontinuation of Study Sites
Study  site parti cipation may be discont inued if Lilly , the invest igator, or the ethical review board 
(ERB) of the study  site judges discont inuat ion of study  site parti cipat ion necessary  for any 
scientific, medical, safet y, regul atory , ethi cal, or other reasons consistent w ith applicable laws, 
regul ations, and GCP.
6.3.5. Discontinuation of the Study
The study  will be di scontinued if Lilly , while considering the rights, safet y, and well -being o f the 
patient(s), judges discont inuat ion of the study  necessary  for any scient ific, medic al, safet y, 
regul atory , ethical , or other reasons consistent with applicable laws, regulat ions, and GCP.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 30
Abemaciclib (LY2835219)7.Treatment
7.1. Materials and Supplies
Abemaciclib
Abemaciclib will be supplied as 50- mg capsules as the 25% w/w formulat ion (C3) for oral  
administration.  The capsules should be stored at room temperature according to the range 
provi ded on the product label and not opened, crushed, or disso lved.
Drug Cocktail
The drug cocktail containing caffeine, warfarin, dextromethorphan, and midazo lam will be 
sourced by  the study  sites.
Caffeine
Commercially available caffeine citrate solution (20 m g/mL )for oral  administrati on.
Warfarin
Commercially available warfarin (brand name Coumadin) as 5 -mg tablets for oral 
administration.
Dextromethor phan 
Commercially available dextromethorphan as 15-mg liquid gel capsules for oral  administrati on.
Midazolam
Commercially available midazolam syrup (2 mg/mL) for oral administration. 
All clinical study  materials will be labeled according to the country’s regulatory  requi rements 
and stored according to the manufacturer’s instructio ns.
7.2. Study Drug Administration
The invest igator or designee is responsible for:
explaining the correct use of the investigational agent(s) to the site personnel or patient,
verify ing that instructions are fo llowed properly, 
maintaining accurate records of study  drug di spensati on, and collect ion, and returning or 
destroying all unused medicat ion to Lilly or its designee at the end of the study .
Patients will  be instructed to conta ct the investigator as soon as possible if they have a complaint 
or probl em with the study  drug(s) so that the situatio n can be assessed.
The first dose of abemaciclib will be given to the patient at the site.  The date and time of the 
dose should be docum ented in the research records.  While pat ients are outsi de the study  site, 
they will be asked to self -administer doses of abemaciclib. The actual time o f all abemaciclib 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 31
Abemaciclib (LY2835219)dose administrations will be recorded in the patients’ diary  during Period 1, Period 2, Period 3 ,
and Period 4.
7.2.1. Dosing Schedule
Period 1
On Day  1,10 m L of 20-mg/mL caffeine citrate solution(100 m g caffeine) , 2 × 5- mgtablet sof 
warfarin, 2 × 15- mgliquid gel capsules of dextromethorphan, and 0.1mL of 2 -mg/mL 
midazo lam syrup will be coadministered orally  with approximately 240 mL of room temperature 
water, in a sitting posit ion.
Patients shoul d not consume food beginning 1 hour before and ending 1 hour after taking study  
drugs .
Period 2
On Days 1 to 12, 4 × 50- mg capsule sof abemacicl ibwill be administered orally  in the m orning 
and evening with approximately  240 mL of room temperature water, in a sitting posit ion.  
Abemaciclib should be taken at approximately the same time each day .  On Day 8, abemaciclib 
will be coadministered with 10 m L of 20- mg/mL caffeine citrate solution(100 m g caffeine) , 
2
× 5-mgtabletsof warf arin, 2 × 15-mgliquid gel capsules of dextrom ethorphan, a nd 0.1 mL of 
2-mg/mL midazo lam syrup with approximately 240 mL of room temperature water, in a sitting 
position.  On Day  8 (coadministrati on wi th the drug cocktail), patients should not consume food 
beginning 1 hour before and ending 1 hour after taking study  drugs .  
If a patient has an INR >2 after the first dose of warfarin, the patient may receive the drug 
cockt ail wit hout warfarin in Period 2 and receive abemaciclib once their INR has stabilized or 
returned to baseline.  
If a patient misses or vomits a dose of abemaciclib , that dose should be omitted (see Section 7.6
for com pliance).  Pati ents will  be asked to take each dose of study  drug wi thin +/ -2 hours of the 
planned dose time or consider the dose a missed dose. 
Periods 3, 4 and Safety Extension Phase  
From  Cycle 1, Period 3 and on Days 1 to 28 in each cycle (Cycle 2 onwards), 4 × 50-mg capsule 
of abemaciclib will be taken orally in the morning and evening.  A bemaciclib should be taken at 
approximately  the same t ime each day.  
A delay  of 7 days in the start of a cy cle (Day  1) for j ustifiable reasons (for example, inclement 
weather, holidays, or weekends) other than toxicit y will be permitted and does not constitute a 
protocol  violation.  A delay of 14 days in t he start of a cycle (Day  1) to allow for recovery  from 
toxicity will be permi tted and does not consti tute a protocol  violation.  A longer delay  may be 
allowed for the start of Cy cle 1 (or Peri od 2), if necessary.  In cases where Cycle 1 (abemaciclib 
dosing ) is significant ly delayed fro m tumor staging during screening, baseline staging may be 
repeated. If there is any quest ion,this may  be discussed with the study  medical  monitor.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 32
Abemaciclib (LY2835219)If a patient requires omissio n of >25% of doses for tolerabilit y at the reduc ed dose level, then 
treatm ent m ay cont inue if the investigator determines that the patient is receiving clinical benefit.
For pati ents requi ring dose reduction(s) due to toxicit y, reescalat ion to a prior dose level is not 
permitted without prior discussio nand agreement with the Lilly CRP/CP or designee.
7.2.2. Dose Adjustments
Period 2
Dose interruptions or adjust ments should be avo ided in Peri od 2 but are allowed if necessary due 
to toxi city.
Upon the first sign of diarrhea, patients should be treated with loper amide and supportive care 
before the abemaciclib dose is o mitted or adj usted (see Section 8.1.3.4.1 ).  If diarrhea is Grade 2 
or worse and does not resolve within 1 day with loperamide and supportive care treatment, then 
the dose should be suspended (until the toxicit y resolves to at least Grade 1) and the dose of 
study  drug m ay be reduced to 150 m g Q12H.  Further dose modificat ion due to diarrhea should 
be discussed wit h the Lilly CRP/CP or designee, and continuation in study  determined jo intly as 
described in Section 7.6.
If it isdeemed the patient must be replaced due to dosing o missions or dose reductions, the 
patient may cont inue on study  to receive abemaciclib and co mplete all other study  procedures for 
secondary  and expl oratory  study  object ives.
Periods 3, 4 ,and Safety Exten sion
Dose adjust ments are allowed during Period 3, Period 4,and the safet y extensio n phase, both 
within a cycle and between cycles following Table JPCB. 7.1.  Study  drug dose reductions are 
outlined in Table JPCB. 7.2.
Before the start of each cycle, drug -related toxicit ies (except alopecia and fat igue) must resolve 
to either baseline or at least Grade 2.  The start of a cy cle may  be delayed up to 14 days to allow 
sufficient time for recovery .  Pati ents not recovering from toxicit y within 14 da ys should be 
discontinued fro m the study .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 33
Abemaciclib (LY2835219)Table JPCB. 7.1. Toxicity Dose Adjustments and Delays of Abemaciclib for 
Study JPCB
Toxicity Type Toxicity Profile and Severity Dose Suspension Dose Reduction
Neutropenia/thrombocytopenia
Section 7.2.2.1Grade 3 which lasts 7 days Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2.Dose MAY be reduced 
by 1 dose level -
investigator’s discretion.
Neutropenia/thrombocytopenia 
Section 7.2.2.1Recurrent Grade 3 (on later cycle)
which lasts 7 daysDose MUST be suspended 
until toxicity resolves to at 
least Grade 2.Dose MAY be reduced 
by 1 dose level -
investigator’s discretion .
Neutropenia/thrombocytopenia   
Section 7.2.2.1Grade 4 which lasts 3 days Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2.Dose MUST be reduced 
by 1 dose level.
Hematologic toxicity:  Patient 
requires administration of 
white blood cell growth 
factors
Section 7.2.2.1Regardless of severity
(Growth factors use according to 
ASCO Guidelines)Dose MUST be suspended 
for at least 48 hours after 
the last dose of white blood 
cell growth factors was 
administered and until 
toxicity resolves to at least 
Grade 2.Dose MUST be reduced 
by 1 dose level unless 
already  performed for 
incidence of toxicity that 
lead to the use of white 
blood cellgrowth factor.
Nonhematologic Toxicity 
(except diarrhea)
Section 7.2.2.2 .1Persistent or recurrent Grade 2 that 
does not resolve with maximal 
supportive measures within 7 days 
to baseline or Grade 1Dose MAY be suspended 
until toxicity resolves to 
either baseline or Grade 1.Dose MAY be reduced 
by 1 dose level -
investigator's discretion.
Nonhematologic Toxicity 
Section 7.2.2.2. 1Grade 3 or 4 Dose MUST be suspended 
until toxicity resolves to 
either baseline or Grade 1.Dose MUST be reduced 
by 1 dose level.
Diarrhea
Section 7.2.2.2. 2Requires hospitalization or Grade 3 
or 4Dose MUST be suspended 
until toxicity resolves to at 
least Grade 1.Dose MUST bereduced 
by 1 dose level.
Diarrhea
Section 7.2.2.2 .2Persistent or recurrent Grade 2 that 
does not resolve with maximal 
supportive measures within 
24hours to at least Grade 1Dose SHOULD be 
suspended until toxicity 
resolves to at least Grade 1.Dose MAY be reduced 
by 1 dose level -
investigator's discretion.
Diarrhea
Section 7.2.2.2. 2Diarrhea recurs despite maximal 
supportive measures after resuming 
same dose level after initial 
Grade 2 diarrheaDose MUST be suspended 
until toxicity resolves to at 
least Grade 1.Dose MUST be reduced 
by 1 dose level.
Abbreviation:  ASCO = American Society of Clinical Oncology.
Note:  MAY =per the investigator’s clinical judgment; SHOULD =not mandatory but highly recommen ded; 
MUST =mandato ry.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 34
Abemaciclib (LY2835219)Table JPCB. 7.2. Dose A djustments for Abemaciclib during Period 3, Period 4,and 
Safety Extension
Dose adjustment Oral dose Frequency
0 200 mg Q12H
1 150 mg Q12H
2 100 mg Q12H
3 50 mg Q 12H
7.2.2.1. Hematologic Toxicity
If a patient experiences Grade 4 neutropenia/thrombocy topeni a, which lasts 3 day s, then dosing 
must be suspended (unt il the toxicit y resolves to at least Grade 2) and the dose of abemaciclib 
must be reduced as outlined in Table JPCB. 7.2.
If a patient experiences Grade 3 neutropenia/thrombocy topeni a, 
which lasts 7 day s, then dosing 
must be suspended (unt il the toxicit y resolves to at least Grade 2) and the dose of abemaciclib 
may be reduced by 1 dose l evel.  If the patient experiences a recurrent episode of Grade 3 
neutropeni a/thrombocy topenia in a later cy cle, which lasts 7 day s, then do sing mustbe 
suspended (unt il the toxicit y resolves to at l east Grade 2) and the dose of abemaciclib may be 
reduced by  1dose l evel.
If a patient requires administration of white blood cell growth factors, the dose of study  drug 
must be suspended for at le ast 48 hours after the last dose of white blood cell growth factors was 
administered and unt il toxicit y resolves to at least Grade 2, then reduced by 1 dose l evel, if a 
dose reduction for the specific event necessitat ing the use of the white blood cell  growth factors 
has not al ready  occurred.
Before the start of each cycle, hematologic toxicit y possibly related to abemaciclib must resolve 
to at l east Grade 2.
7.2.2.2. Nonhematologic Toxicity
7.2.2.2.1. Dose Adjustments for Other Nonhematologic Toxicity
If a patient experiences ≥ Grade 3 nonhematologic toxicit y possibly related to abemaciclib, then 
dosing must be suspended (until the toxicit y reso lves to either baseline or at least Grade 1) and 
the dose of abemaciclib must be reduced as outlined in Table JPCB. 7.2.
If a patient experiences persistent or recurrent Grade 2 nonhematologic toxicit y (except diarrhea; 
refer to Section 7.2.2.2.2 ) possibly related to abemaciclib that does not resolve with maximal 
supportive measures within 7 days to either baseline or Grade 1, then dosing may be suspended 
(until the toxicit y res olves to either baseline or at least Grade 1) and the dose of abemaciclib may  
be reduced as outlined in Table JPCB. 7.2.
Before the start of each cycle, nonhematologic toxicit y (except al opecia and fati gue) possibly 
related to abem aciclib must resolve to either baseline or at least Grade 1.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 35
Abemaciclib (LY2835219)7.2.2.2.2. Diarrhea
A pat ient experiencing diarrhea requiring hospitalization (irrespect ive o f grade, that i s, requi ring 
intravenous [IV] rehy dration) or severe diarrhea (Grade 3 or 4) musthave study treatment 
suspended (unt il the toxicit y resolves to at l east Grade 1) andshould have the study  drug dose 
reduced by  1 dose l evel as outlined in Table JPCB. 7.2.
If a patient experiences persistent or recurrent diarrhea that d oes not resolve wit h maximal 
supportive measures (refer to Section 8.1.3.4.1 ) within 24 hours t o at l east Grade 1, then study  
treatm ent shoul dbe suspended (unt il the toxicit y resolves to at l east Grade 1) and the dose of 
study  drug maybe reduced by 1 dose level as outlined in Table JPCB. 7.2at the discret ion of the 
investigator.  If the same dose level was resumed and diarrhea recurs despite maximal supportive 
measures, the dose of study  drug must be reduced by 1 dose l evel as outlined in Table JPCB. 7.2.
7.3. Method of Assignment to Treatment
Patients who m eet all cri teria for enrollment will be assigned to receive the fixed- sequence of 
treatm ents i n this study .
7.4. Blinding
This is an open -label s tudy.
7.5. Concomitant Therapy
No other chemotherapy , radi otherapy , immunotherapy , cancer -related horm one therapy , or 
experimental drugs will be permitted while the patients are on this study , except for those 
described in Inclusion Criterion [7] in Section 6.1.1 .
The need for radiotherapy  will be cause for early discontinuat ion from the study , with the 
exception of palliat ive radiotherapy ,which is permitted if not being utilized for disease 
progression .  In addit ion, any disease progression requiring other forms of specific antitumor 
therapy  will also necessitate early  discontinuation fro m the study .
Appropriate documentation for all forms of prem edications, supportive care, and concomitant 
medicat ions m ust be captured on the case report form (CRF) .  Patients will be provided with a 
paper diary  in which to record the start and stop times of new conco mitant medicat ionsand
medicat ions taken as needed from the baseline visit until the end of Period 2.
7.5.1. Interactions of Concomitant Medications with Abemaciclib
All conco mitant m edicat ions should be recorded throughout the patient’s participat ion in the 
study .
7.5.1.1. CYP Interactions
Agents considered to be CYP3A inhibitors and CYP3A inducers are excluded fro m use 14 days 
before the first dose of study  drug and through the end of Period 2.  It is recommended that 
CYP3A inducers and CYP3A inhibitors, as well substrate drugs of CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, and CYP3A with narrow therapeutic indices be avoided.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 36
Abemaciclib (LY2835219)7.5.1.2. Endocrine Therapy
Since funct ional loss of Rb activit y is associated wit h resistance to hormonal therapy in breast 
and prostate cancers (reviewed in Knudsen and Knudsen 2008), patients with pr ostate cancer 
progressing on endocrine therapies may in certain cases have that treatment continued while 
receiving study  drug.  Pati ents wi th breast cancer who are receiving aromatase inhibitors 
(letrozole, anastrozole, or exemestane) or antiestrogens (fu lvestrant or tamoxifen) may not 
participate, as the abemaciclib starting dose for this subset of pat ients is 150mg Q12H. Patients 
with prostate cancer may cont inue to receive l uteinizing -horm one-releasing hormone analogue 
therapy  (leuprolide, goserelin, o r triptorelin) during the study .  In addit ion, hormone replacement 
therapy  initiated before study  entry  may be continued.
7.5.1.3. Growth Factors
Patients shoul d receive full supportive care during the trial. Growth factors should not be 
administered to enable a patient to satisfy study  inclusion cri teria.Growth factors may  be used 
in accordance wit h American Societ y of Clinical  Oncol ogy (ASCO) gui delines (Smit h et al . 
2015) if clinically indicated.  Dosing of study  drug m ust be suspended if the administration o f 
white blood cell growth factors is required and must not be recommenced wit hin 48 hours of the 
last dose of growth factors having been administered. Following the administration of white 
blood cell growth factors, the dose of study  drug must be reduced by one dose level , if a dose 
reducti on for the specific event necessitat ing the use of the growth factors has not already 
occurred.  Before the start of each cycle, hematologic toxicit y must resolve to either baseline or 
at least Grade 2.
Erythroid-stimula ting agents (ESAs, including ery thropoi etin and dar bepoetin) or transfusio ns 
shoul d not be administered to enable a pat ient to satisfy study  inclusio n criteria.   
Both ESAs and 
transfusio n therapy  may be used in accordance with American Societ y of Hematol ogy and 
ASCO guidelines (Rizzo et al. 2010), if clinically indicated.
7.5.2. Interactions of Concomitant Medications with Drug Cocktail
Caffeine, warfarin, dextromethorphan, and midazolam are substrates of CYP1A2, CYP2C9, 
CYP2D6, and CYP3A, respect ively.  Thus, drugs that are known inducers and/or inhibitors of 
CYP1A2, CYP2C9, CYP2D6, and CYP3A are specifically excluded prior to 14 day s ofdrug 
cocktail administration and throughout Periods 1 and 2.  Since caffeine is one of the substrate 
drugs being evaluated in this study , consum ption of caffeine -containing beverages and foods 
must be avoided at least 5 day s prior to drug cocktail adminis tration and throughout Periods 1 
and 2. Subjects must also refrain fro m consuming grape fruit juice, Seville oranges ,and St. 
John’s wort 14 day s prior to the cocktail administration and throughout Periods 1 and 2.
The invest igator should refer to the pre scribing label for each drug within the cocktail for 
additional information about the potenti al for drug interact ions.  
For informat ion about contraindicat ions of other drugs indicated in combinat ion with the drug 
cocktail, investigators should refer to the contraindicat ionssection of the package inserts.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 37
Abemaciclib (LY2835219)7.6. Treatment Compliance
The drug cocktail will be administered orally twice at the study  site, under the di rection of  the 
investigator in Periods 1 and 2.  As a result, a patient’s co mpliance with drug coc ktail 
administration is ensured for these periods.  
Patients are expected to be compliant with all doses of study  medicat ion.  Patients should attend 
scheduled clinic visit s and must comply wit h study criteria under their control.  Deviat ion(s) 
from the prescribed dosage regimen should be recorded on the CRF.  
Patient com pliance wi th abemaciclib will be assessed when patients return to the clinic during 
Periods 2, 3 ,and 4.  Compliance will be assessed through review of patient diary, direct 
questioning, and count ing of returned tablets.  Deviat ion(s) from the prescribed dosage regimen 
shoul d be recorded on the CRF.
If a patient misses 2 or more of the planned doses of abemaciclib within 3 consecut ive days prior 
to the drug cocktail dose in Period 2,the patient will need to be replaced, or dosing with the drug 
cocktail may  be delayed to allow for adequate exposure. Delay should only occur on a 
case-by-case basis fo llowing discussio n and agreement with the Lilly CRP/CP or designee. 
Likewise, if dose reduc tion is requi red to l ess than 150m g Q12H or if dose interruptions or 
omissio ns are deemed necessary  during Period 2 for greater than 4consecut ive doses at any t ime, 
the pati ent may reco mmence dosing of abemaciclib with delay of Period 2 drug cocktail dosi ng 
so that abemaciclib steady  state i s achieved (5- 7 days) . 
During the safet y extensio n phase, patient compliance wit h abemaciclib will be assessed and 
recorded at each visit by  count ing returned capsules. 
Similarly, a patient may be considered nonco mpliant if he or she is judged by  the invest igator to 
have intent ionally  or repeatedly taken more than the prescribed amount of medicat ion.  Any  
missed doses will be o mitted and not replaced.  In the event of a missed dose, a patient should 
resum e and continu e dosing beginning with the next scheduled dose.  Potential discontinuation 
of a pati ent due to study  drug noncompliance will be discussed between the invest igator and the 
Lilly CRP/CP or designee before making the final determinat ion for discont inuat ion. If a patient 
is discont inued because of study  drug noncom pliance, the patient may  be replaced.
The fo llowing procedures will be emplo yed to ensure appropriate drug accountabilit y:
• Drug accountabilit y will be emphasized at the study  initiation.
• Drug ac countabilit y will be monitored throughout the study .
• Each patient should be instructed to return all study drug packaging and unused material 
to the study  site at each visi t.  The study  site will  keep a record of all study  drug dispensed to and 
returned by the patients throughout the study .  Study  site personnel  will return or destroy  (as 
requested) all unused study  drug for all patients.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 38
Abemaciclib (LY2835219)7.6.1. Evaluable Patients
Patients who wi thdraw from  the study  before receiving study  drug(s) will be replaced and will 
not b e included in the safet y or efficacy  assessments.  Safet y analyses will be conducted on all 
patients who have received at least 1 dose of study drug.
Any pat ient who does not completethe drug interaction portion of the study (Periods 1 and 2, 
including al l of the PK sampling) at a dose of either 200 mg Q12H or 150 mg Q12H will be 
deem ed nonevaluable for the drug interaction analyses and shoul d be replaced after consultation 
with the invest igator(s) and the Lilly CRP/CP or designee to ensure adequate PK dat a to evaluate 
the drug interaction. Patients who are deemed nonevaluable for drug interaction analyses may 
continue on study ,receive abemaciclib ,and com plete all  other study  procedures for secondary  
and exploratory  study  objectives. 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 39
Abemaciclib (LY2835219)8.Safety , Pharmacokinetic, Pharmacody namic, and 
Efficacy Data Collection
8.1. Safety Evaluations
The safet y and tol erabilit y of abemaciclib have been assessed in nonclinical toxico logy studi es 
and the results from these studies are detailed in the IB.  This Phase 1 study contains detailed 
safet y monitoring that will permit init ial characterization of the safet y profile o f abemaciclib in 
patients.  Study  procedures and their timing, including collect ion of blood and urine samples, are 
described in the Study  Schedule ( Attachment 1 ).
Standard laboratory  tests, including chemistry, hematology , and urinalysis panels, will be 
perform ed.  A pregnancy test will be administe red if applicable.  Other clinical laboratory  tests 
will also be co llected.  Attachment 2 lists the specific tests that will be performed for this study . 
Vital signs, ABPM, and ECGs will also be performed.  
8.1.1. Safety Data Collection and Review
Invest igators are responsible for monitoring the safety of pat ients who have entered into this 
study  and f or alerting Lilly  or its designee to any  event that se ems unusual, even if this event 
may be considered an unant icipated benefit to the patient.  
The invest igator is responsible for the appropriate medical care of the patient during the study.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious, considered related to study  treatm ent or the study , or that caused the patient 
to discont inue before completing the study.  The patient sho uld be f ollowed unt il the event is 
resolved, the event is no longer considered to be drug- related, the event becomes stable or 
returns to baseline, a new treatment is init iated for the patient, or the patient dies or is lost to 
follow-up.  Frequency  of AE and SAE fo llow-up evaluat ion is left to the discret ion of the 
investigator.
The timing of all safet y evaluat ions is shown in the Study  Schedule ( Attachm ent 1 ).  
Table JPCB. 8.1presents a summary o f AE and SAE reporting guidelines.  
8.1.2. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.  A clinical study  AE is any untoward medical occurrence 
in a pati ent or clinical invest igation subject administered a pharmaceut ical product and which 
does not necess arily have a causal  relati onship wi th this treatm ent.  An AE can therefore be any  
unfavorable and unintended sign (including an abnormal laboratory  finding), symptom, or 
disease tem porally associ ated wi th the use of m edicinal (invest igational) product, whe ther or not 
related to the medicinal (invest igational) product.  Any clinically significant findings fro m labs, 
vital sign m easurements, and so on that occur should also be reported to Lilly  or its designee as 
an AE.  Lack of drug effect is not an AE in cl inical studies because the purpose of the clinical 
study  is to establish drug effect.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 40
Abemaciclib (LY2835219)The invest igator, monitor, and sponsor will review the collected data regularly for evidence of 
AEs.  All pat ients will be assessed routinely for AEs as outlined in the S tudy Schedule.  Patients 
will be provided with a paper diary in which to record the start and stop times of all AEs 
experienced fro m the baseline visit until  the end of Peri od 2.
The Commo n Termino logy Criteria for Adverse Events (CTCAE) Version 4.0 will s erve as the 
reference document for choosing appropriate termino logy for, and grading the severit y of, all 
AEs and other symptoms.  All AEs observed will be graded using CTCAE v 4.0.  Any  minor 
versio n of CTCAE v 4.0(for example, Versio n 4.03) maybe used for this study .  Minor CTCAE 
v 4.0 updates from the NCI will not necessitate a protocol amendment.  For AEs without 
matching termino logy within the CTCAE v 4.0 criteri a, the invest igator will be responsible for 
select ing the appropriate system organ class and assessing severit y grade based on the intensit y 
of the event.  Note that both CTCAE term (actual or coded) and severit y grade m ust be selected 
by study  site personnel  and collected on the CRF.  This collection is in addit ion to verbat im text 
used to de scribe the AE.
In addit ion to collect ing the AE verbat im, the CTCAE term, and the CTCAE severit y grade, AE 
verbat im text will also be mapped by the sponsor or designee to corresponding termino logy 
within the Medical Dict ionary for Regulatory  Activities dic tionary .
Cases of pregnancy that occur during maternal or paternal exposures to study  drug shoul d be 
reported.  Data on fetal outcome and breastfeeding should be collected, if feasible, for regulatory 
reporting and drug safet y evaluat ion.
Upon docum entati on of pregnancy , the pati ent m ust be rem oved from  the study  and treatment 
with study  drug(s) m ust be stopped immediately.
For all enrolled pat ients, study  site personnel will record the occurrence and nature of each 
patient’s preexist ing condit ions, includi ng clinically  significant si gns and symptoms of the 
disease under treatment in the study .  While the pati ent is on study , site personnel will record any  
change in these preexist ing condit ion(s) and the occurrence and nature of any  AEs.  In addi tion 
all AEsrelated to protocol  procedures are reported to Lilly or designee.
If a patient’s dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lilly  or its desi gnee via the eCRF the circumstances and data
leading to any  such dosage reduction or discont inuation of treatment. 
Invest igators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure or study  drug via the eCRF.
The inves tigator deci des whether he or she interprets the observed AEs as either related to 
disease, to the study  medicat ion, study  procedure, or other concomitant treatment or pathologies.  
To assess the relat ionship of the AE to the study  drug, the fo llowing term inologies are defined:
Related :  a di rect cause and effect relat ionship between the study  treatm ent and 
the AE i s likely.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 41
Abemaciclib (LY2835219)Possibly related :  a cause and effect relat ionship between the study  treatm ent and 
the AE has not been demonstrated at this time a nd is not probable, but is also not 
impossible.
Unrelated :  without questi on, the AE i s defini tely not associ ated wi th the study  
treatm ent.
As per Lilly’s standard operating procedures, all “related” and “possibly  related” AEs and SAEs 
will be defined as related to study  drug.
8.1.2.1. Serious Adverse Events
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
Planned hospi talizat ions or procedures for underlying preexist ing condit ions that are al ready  
recorded in the patient’s medical history  at the time of study  enrollment shoul d not be consi dered 
SAEs.  Hospitalizat ion or prolongat ion of hospitalization wit hout a precipitating clinical AE (for 
example, for the administration of stud y treatm ent or other protocol -requi red procedure) shoul d 
not be considered SAEs.
An SAE is any  AE during thi s study  that resul ts in one of the following outcomes:
death
initialor prol onged inpatient hospitalizat ion (except for study  drug 
administration)
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
considered significant by  the in vestigator for any other reason
Important m edical events that may not result in death, be life -threatening, or require 
hospi talizati on may  be considered SAEs when, based on appropriate medical judgment, they  
may jeopardize the patient and may require medical or surgical intervent ion to prevent one of the 
outcom es listed in this definit ion. 
Serious adverse events due to disease progression, including death, should not be reported unless 
the invest igator deems them to be possibly relate d to the study  drug.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th offici al notificati on on study -specific SAE forms.  This 
24-hour notificat ion requirement refers to the init ial SAE information and all fo llow -up SAE 
inform ation.  
If an invest igator becomes aware of SAEs occurring after the patient’s participation in the trial
has ended, and the invest igator believes that the SAE is related to a protocol procedure or study 
drug, the invest igator should report the SAEs to the sponsor and the SAEs will be entered in the 
Lilly Safety  System .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 42
Abemaciclib (LY2835219)Inform ation on SAEs expected in the stu dy popul ation independent of drug exposure and that 
will be assessed by  the sponsor in aggregate periodically during the course of the trial may  be 
found in the IB.  
8.1.2.2. Adverse Event and Serious Adverse Event Reporting
Data on SAEs that occur before the end of trial will be stored in the collect ion database and the 
Lilly Safety  System .
8.1.2.2.1. Prior to Administration of Study Drug(s)
During screening, all AEs and SAEs (regardless of relatedness to protocol procedures) are 
collected after the patient has signed the in formed consent form (ICF) .  For patients who do not 
enroll in the tri al (that is, have not received at least 1 dose of abemaciclib ), only AEs and SAEs 
related to protocol  procedure s are required to be collected.
8.1.2.2.2. On Study Treatment
All AEs and SAEs, regardl ess of relatedness to study  drug(s) or protocol procedures, occurring 
while the patient is receiving study  drug m ust be reported to Lilly  or its designee.  A patient is 
considered to be receiving study  drug from  the time he/she receives the first dose of s tudy drug 
to when he/she receives the last dose of study  drug.
8.1.2.2.3. Follow -Up Visit
All AEs and SAEs, regardless of relatedness to study  drug(s) or protocol procedures, occurring 
during the fo llow-up visit must be reported to Lilly or its designee.  For patient s not continuing 
in the safet y extensi on phase, the follow -up visit should occur after a washout period of at least 
10days from the l ast abemaciclib dose in Period 2.  For patients participat ing in the safety 
extensio n phase, a fo llow-up visit should occu r approximately  10 days after the l ast abemaciclib 
dose.  At this fo llow-up visit, the patient will be required to have specific safet y assessments 
(Attachm ent 1 ).  The timing of these safety assessments are outlined in Attachm ent 1 .
Following the safet y assessments, which mark the end of the follow-up visit, the patient will be 
discontinued fro m the study , unless there is an ongoing AE or SAE that is possibly  related to 
study  drug.  In thi s instance, the patient should be followed in subsequent fo llow-up visit s unt il 
the event is resolved, the event i s no l onger considered to be drug -related, the event becomes 
stable or returns to baseline, a new treatment is init iated for the patient, or the patient dies or is 
lost to foll ow-up.
If it is deemed to be in the best interest of the patient to star t a new ant icancer treatment prior to 
the scheduled end of the fo llow-up visit, the fo llow-up vi sit durati on may  be shortened. In this 
case, the fo llow-up assessments should be co mpleted prior to the init iation of the new therapy.
After the fo llow-up visi t, AEs are not requi red to be reported unless the invest igator feels the 
AEs were related to either study  drug or a protocol procedure. If an investigator becomes aware 
of SAEs believed to be related to protocol procedures or study  drug, the invest igator shoul d 
report the SAE to the sponsor, and the SAE will be entered in the Lilly Safety  System .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 43
Abemaciclib (LY2835219)8.1.2.3. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are SAEs that are not listed in the 
Development Core Safet yInformati on or in the IB and that the invest igator ident ifies as related 
to study  drug or procedure.  The United States 21 CFR 312.32, the European Unio n Clinical 
Trial Di rective 2001/20/EC and the associated detailed guidances or nati onal regul atory  
requi rements in participat ing countries require the reporting of SUSARs.  Lilly has procedures 
that will be fo llowed for the recording and expedit ed reporting of SUSARs that are consistent 
with global regulatory  regulati ons and the associ ated detailed guid ances.
8.1.2.4. Summary of Adverse Event/Serious Adverse Event Reporting Guidelines
The AE and SAE reporting guidelines are summarized in Table JPCB. 8.1.
Table JPCB. 8
.1. Adverse Event and Serious A dverse Reporting Guidelines for 
Study JPCB
Timing Types of AEs/SAEs Reported 
Prestudy (baseline assessments)
(Starts at the signing of informed consent and ends 
just before the first dose of study drug)Preexisting conditions
All AEs/SAEs possibly related to protocol 
procedures
On therapy
(Starts at first dose of study drug(s) and ends at last 
dose of study drug[s])All AEs/SAEs regardless of relatedness
Follow -up visit
End of Period 2:  starts after the last PK sample and 
ends when end of study safety assessments are 
completed
Safety extension:  starts just after the last dose of 
study drugs and ends when end of study safety 
assessments are completedAll AEs/SAEs r egardless of relatedness
Subsequent follow -up visits, if necessary Ongoing or new AEs/SAEs possibly related to 
study drug or protocol procedures
Abbreviations:  AE = adverse event; PK = pharmacokinetic; SAE = serious adverse event.
8.1.3. Other Safety Measures
8.1.3.1. Vital Signs
Blood pressure, pulse rate, and body  temperature will  be measured as specified in the Study  
Schedule and as clinically  indicated ( Attachment 1 ).
Blood pressure and pulse rate should be measured after at least 5 minutes supine ,
semi-recumbent , or si tting; the posit ion shoul d be recorded .
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture-induced symptoms.  Addit ional vital signs may be m easured during each study  period if 
warranted and agreed upon between the sponsor and invest igator.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 44
Abemaciclib (LY2835219)8.1.3.2. Ambulatory Blood Pressure Monitoring
Blood pressure and pulse rate will be measured using an ABPM device over a 12 -hour period for 
acclimat ion and over 24 -hour periods for study assessments as specified in the Study  Schedule 
(Attachm ent 1 ).
The A BPM device will be fitted to the patient’s nondo minant arm and will record ambulatory 
blood pressure and pulse rate every  30 minutes during the day  (for exam ple, 0700 hours to 
2200 hours) and every 2 hours at night (for example, 2200 hours to 0700 hours). For each 
24-hour ABPM collect ion peri od, pati ents will be encouraged to maintain light activit y (that is, 
walking) and keep their same routine during the ABPM collect ion peri od.  ABPM data will not 
be used for patient management.
8.1.3.3. Electrocardiograms
For ea ch patient, a 12 -lead di gital ECG will  be collected according to the Study  Schedule 
(Attachm ent 1 ).  Patients must be supine or semi-recumbent for approximately 5 to 10 minutes 
before ECG collect ion and remain supine or semi -recumbent but awake during ECG collect ion.  
Electrocardiograms may be obtained at addit ional times ,when deemed clinically necessary .  
Collect ion of more ECGs (more replicates) than expected at a particular time point is allowed to 
ensure high qualit y records. 
Electrocardiograms will be interpreted by  
a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG colle ction as possible, and ideally while the 
patient is st ill present, to determine whether the patient meets entry  criteria at the rel evant visit(s) 
and for immediate patient management, should any clinically relevant findings be identified.  
If a clinically significant quantitative or qualitat ive change fro m baseline is ident ified after 
enrollment, the investigator will assess the patientfor symptom s (for example, pal pitations, near 
syncope, syncope) to determine whether the patientcan continue in the stud y.  The invest igator 
or qualified designee is responsible for determining if any change in patientmanagement i s 
needed and must document his/her review of the ECG printed at the time of evaluat ion.
8.1.3.4. Bowel Habits
8.1.3.4.1. Diarrhea Management
In the event of diarrhea , supportive measures should be init iated as early  as possible.  These 
include the fo llowing: 
Upon enrollment, patients should receive instructions in the event that a patient would 
experience diarrhea 
At the first sign o f loose stools, the patient shoul d initiate anti -diarrheal  therapy (e.g. 
loperamide) and notify the investigator/site for further instructions and appropriate 
follow-up. 
Patients shoul d also be encouraged to drink fluids (e.g., 8 to 10 glasses of clear liquids 
per day ). 
Site personnel s hould assess response within 1 day. 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 45
Abemaciclib (LY2835219)If diarrhea does not resolve with ant i-diarrheal therapy  within 1 day to either baseline or 
Grade 1, abemaciclib should be suspended or the dose m ay be reduced until diarrhea is 
resolved to baseline or Grade 1(see Sect ion 7.2.2 ). 
When abemaciclib reco mmences ,dosing should be adjusted as outlined in 
Table JPCB. 7.1. 
In severe cases of diarrhea, measuring neutrophil counts and body temperature and proactively 
managing diarrhea wit h ant i
-diarrheal  agents should be considered.
If diarrhea is severe (requi ring IV rehydrati on) and/or associated with fever or severe 
neutropeni a, broad -spectrum ant ibiotics such as fluoroquinolones must be prescribed.
Patients wi th severe di arrhea or any  grade of di arrhea associated with severe nausea or vomit ing 
shoul d be care fully m onitored and given IV fluid (IV hy dration) and electroly te repl acement .
Osmolality will be measured to assist with evaluation of any change in vo lume.  In severe cases 
of diarrhea, the measuring of neutrophil counts and body  temperature and proactiv e management 
of diarrhea wi th anti-diarrheal agents should be considered.
8.1.3.4.2. Patient Diary
An electronic patient di ary to collect date and time of bowel movements, a Bristol Stool Chart ,
and drug administration will be completed daily by the patient, starting at baseline and requi red 
through end of Period 2.  Patients participat ing in Period 3 and 4 should continue complet ing 
diary entri es through end of Period 4.   Patients will also receive a paper diary  in which to record 
the start and stop times of all AEs, new conco mitant m edicat ionsandmedications taken as 
needed from the baseline visit unt il the end of Period 2.
8.1.3.4.3. Patient Reported Outcomes
Collect ion of PRO data will help characterize diarrhea as an exploratory  analysis based on:
Single da ily items generated by  the team
Weekly items based on the FACIT -D
Patient reported questionnaires should be completed by  patients when a language translation is 
available in which the pat ient is fluent or literate.
At each time po int identified in the Study  Schedule (Attachment 1 ), a copy  of the PRO i tems 
shoul d be com pleted by  the pati ent pri or to extensive interaction wit h site staff and study  drug 
administra tion.
8.1.4. Safety Monitoring
The Lilly CRP/ Clinical Research Scient ist (CRS )will mo nitor safety  data thro ughout the course 
of the study .
Representatives from Lilly Glo bal Patient Safet y will specifically  monitor SAEs.  Lilly  will 
review SAEs wit hin time frames mandated by  company standard operating procedures.  The 
Lilly CRP/CRS will, as is appropriate, consult with the funct ionally  independent Gl obal Pati ent 
Safety therapeuti c area physician or clinical research scient ist, and periodically review:
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 46
Abemaciclib (LY2835219)trends in sa fety data,
laboratory  analy tes,
AEs,
if a study  patient experiences elevated ALT >5X ULN and elevated total bilirubin >2X 
ULN, clinical and laboratory  monitoring shoul d be ini tiated by  the invest igator. 
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities.  To ensure patient safety  and comply  with regulatory  guidance, the 
investigator is to consult with the Lilly CRP/CP or designee regarding co llection of specific 
recommended clinical information and fo llow-up laboratory  tests (see Attachment 3 ).
8.1.5. Complaint Handling
Lilly co llects complaint s on study  drugs used in clinical studies in order to ensure the safet y of 
study  participants, m onitor quali ty, and f acilitate process and product improvements.
Com plaint s related to com parator drugs or concomitant drugs are reported directly to the 
manufa cturers of those drugs in accordance wit h the package insert.
The invest igator or his/her designee is responsible for handling the fo llowing aspects of the 
complaint process in accordance with the instructions provided for this study :
recording a complet e descri ption of the complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed complaint form within 24 hours to Lilly or its designee
If the invest igator is asked to return the product for invest igation, he/she will return a copy  of the 
product complaint form with the product.
8.2. Sample Collection and Testing
Attachm ent 1 lists the schedule for sam ple collect ions in this study.
Attachm ent 2 lists the specific tests that will be performed for this study.  
Attachm ent 6 provides a summary o f the estimated maximum number and volume o f invasive 
samples, for all sampling, during the study .
8.2.1. Samples for Study Qualificatio n and Health Monitoring
Blood and urine samples will be collected to determine whether patients meet 
inclusio n/excl usion criteria and to m onitor pati ent heal th.
Invest igators must document their review of each laboratory  safety  report.
Samples co llected fo r specified laboratory  tests will  be destroy ed wi thin 60 days of receipt of 
confirmed test results.  Tests are run and confirmed prompt ly whenever scient ifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain sampl es 
to batch the tests run, or to retain the samples until the end of the study  to confirm  that the resul ts 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 47
Abemaciclib (LY2835219)are valid.  Certain samples may be retained for a longer period, if necessary, to comply wit h 
applicable laws, regulat ions, or l aboratory  certificati on standards.
8.2.2. Samples for Drug Concentration and Pharmacodynamic 
Measurements 
8.2.2.1. Pharmacokinetic Samples
At the visit s and t imes specified in the Study Schedule (Attachment 1 ), venous blood samples 
will be co llected to determine the plasma concentrations o f abemaciclib, caffeine, S- warfarin, 
dextrom ethorphan, and midazo lam.  A maximum of 3 sam ples m ay be collected at addit ional 
time points during the study  if warranted and agreed upon between both the invest igator and 
Lilly.  Instructions for the collect ion and handling of blood samples will be provided by the 
sponsor .  The actual date and time (24 -hour clock time) of each sampling will be recorded.
These s amples will be analyzed at a laboratory  designated by  the sponsor.  Pl asma 
concentrations of each analyt e will be assayed using a validated method.
The PK samples will be stored at a facilit y designated by  the spo nsor.
The rem aining pl asma f rom the sam ples collected for PKmay be pooled and used for 
exploratory  metabo lism work as deemed appropriate.
Bioanaly tical samples collected to m easure invest igational product concentration will be retained 
for a maximum of 1 year following last patient visit for the study .  
8.2.2.2. Pharmacodynamic Samples
At the visit s and t imes specified in the Study Schedule ( Attachment 1 ), venous blood samples 
will be co llected to determine INR (see Attachment for the blood sampling summary).  Analysis 
of PTor INR will be performed by local labs. Local labs for PT orINR will be co llected for 
patient management and PD analyses. 
Guidance Regarding Elevation of the INR
Patients will  receive a single dose of warfarin (10 mg) as part of the drug cocktail in Period 1 and 
Period 2:
Period 1: If a patient has an INR >2 after the first dose of warfarin, the patient should not 
receive warfarin ag ain in the drug cocktail in Period 2, but may  be all owed to enter 
Period 2 and receive abemaciclib once their INR has stabilized or returned to baseline.  
The patient may be repl aced.
Period 2: For any patient found to have an INR 4 after the administrat ion of warfarin in 
Period 2, further abemaciclib dosing should be held until the INR stabilizes or returns to 
baseline (refer to Section 7.2.2 ).
Addit ionally  the f ollowing guidance is provided (Cushman et al. 2014) :
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 48
Abemaciclib (LY2835219)If the INR is >4 but <9, and there is no significant bleeding, oral vitamin K (1 to 2.5mg) 
is reco mmended.
If the INR is 9, and there is no significant bleeding, oral vitamin K ( 2.5to 5 mg) is 
recommended .
In the case of significant bleeding, addit ional supporti ve care i s recommended (for 
example, prothrombin co mplex concentrates and vitamin K 10 mg, by oral or slow 
intravenous infusio n).
The INR should be repeated according to the Study Schedule (Attachm ent 1 ); additional INR 
samples may  be collected daily , if needed, unt il the INR has returned to baseline. The final 
decisio nas to whether to administer vitamin K or other therapy  shoul d take into account the 
investigator’s assessment of the patient.
Lilly should be notified in the case of the INR elevations as described above. 
The samples will be ident ified by the pat ient num ber (coded) and stored for up a maximum o f 
1year after the last patient visit for the study at a facilit y selected by  the sponsor.  
8.2.3. Samples for Evaluation of Renal Function
At the visit s and t imes specified in the Study Schedule (Attachment 1 ), venous blood samples 
(approximately 5 mL each) will be co llected to determine serum concentrations o f renal markers, 
including creatinine, cystatin- C, and NGAL, and urine samples (at least 5 mL and up to 120 mL) 
will be co llected to determine urinary concentrations o f renal markers, including creat inine, 
KIM -1, and NGAL.  These laboratory  tests will  be perform ed by a central laboratory  selected by  
Lilly.  Other markers of renal funct ion may be evaluated if deemed appropriate.
The samples will be ident ified by pat ient number and will be stored for up to a maximum of 
15years after the last patient visit for the study .
8.2.4. Samples for Tailoring Biomarkers 
There is growing evidence that genetic variat ion may impact a pati ent’s response to therapy .  
Variable response to therapy  may be due to genetic determinants that impact drug absorption, 
distribut ion, metabo lism, and excretion, the mechanism of act ion of the drug, the disease 
etiology and/or the m olecular subt ype of the disease being treated.  Therefore, where local 
regul ations and ERBs allo w, a bl ood sam ple will be collected for pharmacogenet ic analysis.  
Samples will  be stored and analysis may  be performed on biomarker variants thought to play a 
role in cancer, including, but not limited to, genes invo lved in regulat ion of the cell cycle to 
evaluate their associat ion with observed clinical outcomes to abemaciclib . 
In the event of an unexpected AE or the observ ation of unusual response, the pharmacogenetic 
biomarker samples may  be genoty ped and analysis may  be perform ed to eval uate a genet ic 
associ ation with response to study  drug.  These investigations may be limited to a focused 
candidate gene study  or, if app ropri ate, genom e-wide analysis may be performed to identify 
regions of the genome associated with the variability  observed in drug response.  The 
pharmacogenet ic biomarker samples will only  be used for invest igations rel ated to di sease and 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 49
Abemaciclib (LY2835219)drug or class o fdrugs under study  in the context of this clinical program.  They  will not be used 
for broad expl oratory  unspecified disease or population genet ic analysis.
The samples will be coded with the patient number and stored for up to a maximum 15 years 
after the last patient visit for the study at a facilit y selected by  the sponsor.  The samples and any 
data generated from them can only be linked back to the patient by  investi gator si te personnel.  
The durati on allows the sponsor to respond to regulatory  requests related to the study  drug.
Samples will  be destroy ed according to a process consistent with local regulat ion.
8.2.5. CYP Genotype Evaluation
A single blood sample will be co llected from patients to determine the CYP2C9, CYP2D6, 
CYP3A 4, and CYP3A5 genoty pe status during screening.
8.3. Efficacy Evaluations
Refer to Attachment 1 for details regarding the timing of specific efficacy measures.  
Tumor assessments w ill be conducted per standard of care.  Response and progression for tumors 
will be evaluated using RECIST versio n 1.1 (Eisenhauer et al. 2009).
8.3.1. Prestudy
No m ore than 4 weeks before enrolling in the study , each pati ent’s full extent of disease will be 
assessed by  1 or m ore of the following relevant radio logical  tests for tum or measurement:
computed tom ography  (CT) scan
magnet ic resonance imaging (MRI)
chest x -ray
bone scan
No m ore than 2 weeks (14 day s) pri or to enrolling in the study , each patient’s full extent of 
disease will  also be assessed wit h:  
tumor measurement of palpable or visible lesio ns (refer to RECIST 1.1)
evaluat ion of tum or markers, if indicated
8.3.2. During the Study
At the intervals stated in the Study  Schedule ( Attachment 1 ), efficacy will be examined in each 
patient by  the f ollowing evaluat ions:  
ECOG performance status ( Attachment 5) 
tumor measurement of palpable or visible lesio ns  
imaging studies of invo lved disease sites should be repeated in appropriate patients per 
standard of care, approximately every 2 cycles (approximately 4 to 8 weeks).  This 
shoul d include the same methods and techniques used at baseline to ensure that any  
response may be validated.  
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 50
Abemaciclib (LY2835219)All lesion assessments, whether by physical examinat ion or radio logical method s, must be 
repeated by  the same m ethod at l east 4 weeks follo wing the init ial observation o f an object ive 
response for response confirmat ion.
8.3.3. Poststudy Follow -Up
The poststudy  evaluat ion peri od will begin when the pat ient discont inues treatment from the 
safety extensi on peri od for any  reason and will end approximately 10 days following the last 
abemaciclib dose, when another therapy  is init iated, or when the patient dies.  Reasonable efforts 
will be made to fo llow any pat ient with an ongoing com plete respon se or partial response at the 
time of study  discont inuat ion.  In appropriate patients, tumor measurements and imaging studies 
will be performed at 4 -to 8-week intervals up unt il 30 days after final abemaciclib dose, when 
another therapy  is init iated, when there is disease progression, or when the patient dies.  All 
patients will  be evaluated for ECOG performance status (Attachment 5) at the poststudy
follow-up visit.
8.4. Procedure/Sampling Compliance
Every  attem pt will be m ade to enroll patients who have the ability to understand and co mply 
with instructi ons.  Noncom pliant pati ents m ay be discontinued from the study .
The collection t imes of safet y assessm ents, PKsamples, and efficacy measurements are given as 
targets, to be achieved within reasonable limit s.  The scheduled time points may be subject to 
minor al terati ons; however, the actual collect ion time must be correctly recorded on the eCRF.
The sch eduled collect ion times may be modified by the sponsor based on analysis of the safet y 
and PKinformat ion obtained during the study .  Any  major m odificat ions that might affect the 
conduct of the study , pati ent safet y, and/or data integrit y will be detailed in a protocol 
amendment.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 51
Abemaciclib (LY2835219)9.Data Management Methods
9.1. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -uptraining to instruct the invest igators and study  coordinators.  This sessio n 
will give instruction on the protocol, the completion of the CRFs, and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study site personnel by mail, 
telephone, and/or fax
review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collect ion
conduct a qualit y review of the database. 
In addit ion, Lilly or its representatives will perio dically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
Toensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable 
data, the invest igator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study .  If requested, the 
investigator will provide the sponsor, applicable regulatory  agencies, and applicable IRB/ERBs 
with direct access to the original source documents.
9.2. Data Capture S ystems
9.2.1. Case Report Form
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  the si te into the sponsor -provided electronic data capture system.
Any data for which paper documentation provided by the patient will serve as the source 
docum ent will be identified and documented by  each si te in that si te’s study  file.  Paper 
docum entati on provi ded by  the pat ient may include, for example, a paper diary  to collect 
patient-reported outcome measures (for example, a rating scale), a daily dosing schedule or an
event di ary. 
If informat ion reported during an office visit differs from that recorded in the paper diaries, the 
source data (collected during patient interview) will supersede for purposes of collection in the 
CRF.
For data handled by a data management third-party organization (TPO), CRF data and some or 
all data that are related will be managed and stored electronically in the TPO system.   
Subsequent to the final database lock, validated data will be transferred to the Lilly  data 
warehouse, using standa rd Lilly  file transfer processes.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 52
Abemaciclib (LY2835219)For data handled by the sponsor internally, CRF data and some or all data that are related will be 
managed by  the sponsor and stored electronically in the sponsor’s system.
9.2.2. Ancillary Data
Data m anaged by  a central  vendor w ill be stored electronically in the central vendor’s database 
system .  Data will subsequent ly be transferred from the central vendor to the Lilly data 
warehouse.  
Bioanaly tical data will  be stored electronically in the bioanaly tical laboratory ’s database.   Data 
will subsequently be transferred fro m the bioanaly tical laboratory  to the Lilly  data warehouse. 
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
Data from ePRO forms (if used ) will  be transferred from  the ePRO vendor to the Lilly data 
warehouse.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 53
Abemaciclib (LY2835219)10. Data A nalyses
10.1. General Considerations
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee.
The interpretati on of the study  results will be the responsibilit y of the invest igator with the Lilly 
CRP/CP or designee, pharmacokinet icist, and statistician.  The CRP/CP and statistician will also 
be responsible for the appropriate conduct of an internal  review for both the final study  report 
and any  study -related m aterial to be authori zed by  Lilly for publication.
Pharmacokinet ic analyses will be conducted on data from patients who have received at least 
1dose of the study  drug and have had samples collected.  
10.2. Patient Disposition
All patient discont inuat ions will be documented, and the extent of each pat ient’s participat ion in 
the study  will be reported.  If known, a reason for their discont inuation will be given.
10.3. Patient Characteristics
Patient characterist ics will include a summary o f the fo llowing:
patient dem ographics including age, sex, screening height and weight, and screening 
body  mass index will be reported
baseline disease characteristics
prior disease -related therapies 
concomitant medicat ions.
Other patient characterist ics will be summarized as deemed appropriate.
10.4. Safety Analyses
All patients who receive at least 1 dose of study  drug will be evaluated for safet y and toxi city.  
Adverse event terms and severit y grades will be assigned by the investigator using CTCAE, 
Versi on 4.0).
Safety analyses will include summaries of the fo llowing:
AEs, including severit y and possible rel ationship to study  drug
dose adjustments 
clinical laboratory  values including markers of renal funct ion
vital signs 
ABPM data
ECGs
bowel  habit data
-
diarrhea dia ry and stool  assessment
- d iarrhea -related ePRO i tems
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 54
Abemaciclib (LY2835219)An exploratory  safet y analysis will assess the impact of abemaciclib on markers of renal 
funct ion, levels of creat inine, cystatin -C, KIM -1, and NGAL at predose (baseline) will be 
compared to postdose leve ls and results will be summarized using standard descript ive statistics.
Further analysis details will be described in the statist ical analysis plan. 
10.5. Pharmacokinetic Analyses
Pharmacokinet ic parameter estimates for caffeine, S -warfarin, dextromethorphan, and 
midazo lam will be calculated by  standard noncompartm ental  methods of analysis.
The primary  parameters for analysis will be C max, AUC from zero to infinit y (AUC[0 -∞]), and 
tmax.  Other noncompart mental parameters, such as AUC fro m time zero to time t, w here t is the 
last time point with a measurable concentration (AUC[0 -tlast]), time of t 1/2, apparent clearance, 
and apparent volume of distribution may be reported.   Additional exploratory analyses on the 
components of the drug cocktail or abemaciclib will be perform ed if warranted by data .
Pharmacokinet icparameter estimates will be evaluated to delineate effects of drug interaction. 
Caffeine, warfarin, dextromethorphan, and midazolam administered in the absence of 
abemaciclib will represent the reference treatments and be analyzed separately.  Each drug 
administered with abemaciclib will represent the test treatments.  Log -transformed C maxand 
AUC(0 -∞) estimates will be evaluated in a linear mixed -effects analysis o f variance model wit h 
a fixed effect for treatment and a random effect for subject.  The treatment differences will be 
back-transformed to present the ratios of geometric means and the corresponding 90% CIs.
The t maxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the median difference 
based on the observed medians, 90% CIs, and p -values from the Wilcoxon test will be 
calculated.
The inter -and intra -subject variabilit y will be reported for e ach probe drug.
Trough pl asma concentrations of abemaciclib will be listed.
10.6. Pharmacodynamic Analyses
Area under the INR curve (AUC INR) and m aximum  observed INR response (INR max) will be 
calculated to quantify the action of warfarin.
The PD param eters AUC INRand INR maxwill be evaluated statistically  to delineate the effect of 
abemaciclib on INR.  A linear mixed -effects m odel with log-transform ed PD param eter as a 
response variable, predose INR as a covariate, treatment as a fixed effect, and subject as a 
random effect.  For each of these PD parameters, the statist ical inference will be made using the 
test treatm ent of warfarin + abemaciclib and the reference treatment of warfarin in the absence of 
abemaciclib.  The geometric means for the treatments and the ratios of  geom etric m eans for 
AUC INRand INR max, between the test and reference treatments with 90% CIs will be established.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 55
Abemaciclib (LY2835219)10.7. Efficacy
The study  was not designed to make an efficacy  assessment.  However, any  tumor response data 
will be tabulated.
10.8. Interim An alyses
An interim analysis, which will serve as the final analysis for the primary object ive, is planned 
for this study .  Thi s interim analysis will be completed after the last patient has co mpleted 
Period2.
Patients will  be allowed to continue receiving abemaciclib during Peri od 3, 4 ,and the safet y 
extensio n phase unt il discont inuat ion criteria are met (such as progressive disease or 
unacceptable toxicit y).  A final analysis and final study  report will be completed after the last 
patient visi t has occurr ed for this extensio n phase.
Two addit ional interim analyses may be conducted:  one analysis will be conducted after 
approximately  half of the pati ents have com pleted Peri ods 1 and 2, as a preliminary  assessment 
of the m agnitude of  any observed effect on b lood pressure.  No changes to the study  design are 
planned.  Another analysis will be conducted after the last patient has completed Period 4 and a 
preliminary study  report will be written.  
Unplanned interims may be conducted if deemed necessary by Lilly study  team .
This is an open -label study .  Data m ay be analyzed while the trial is ongoing.  An Assessment 
Committee will not be formed.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 56
Abemaciclib (LY2835219)11. Informed Consent, Ethical Review, and 
Regulatory Considerations
11.1. Informed Consent
The invest igator is responsible for en suring that the pati ent understands the potential risks and 
benefits of part icipating in the study, including answering any questions the patient may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the patient’s willingness to continue his or her participat ion in the study  in a timely manner.
The ICF will be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in simple terms before the patient is entered into the study  and to document that the 
patient is sat isfied with his or her understanding o f the potential risks and benefits o f 
participat ing in the study and desires to participate in the study.
The invest igator is ult imately responsible for ensuring that informed cons ent is given by each 
patient or l egal representati ve before the study  is started.  Thi s includes obtaining the appropriate 
signatures , time of consent, and dates on the ICF prior to the performance of any protocol 
procedures and prior to the administration of study drug. 
11.2. Ethical Review
Lilly or i ts representatives must approve all ICFs before they  are used at invest igative sites(s).  
All ICFs must be co mpliant with the ICH guideline on GCP.  
Docum entati on of  ERB approval  of the protocol and the ICF must b e provided to Lilly  before the 
study  may begin at the investi gative si te(s).  The ERB(s) will review the protocol as required.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF
relevant curri cula vi tae
11.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
1) consensus ethics principles derived fro m internati onal ethics gui delines, including the 
Declaration of Helsinki and Council forInternational Organizat ionsofMedical Sciences
(CIOMS ) Internati onal Ethical  Guidelines 
2) the ICH GCP Guideline [E6]
3) applicable laws and regulat ions.
The investigator or designee will prompt ly submi t the protocol  to applicable ERB(s).
Some of the obligat ions of the sponsor will be assigned to a TPO.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 57
Abemaciclib (LY2835219)An identificat ion code assigned by the invest igator to each patient will be used in lieu of the 
patient’s name to protect the patient’s ident ity when reporting AEs and/or other study -related 
data.
11.3.1. Investigator Information
Site-specific contact informat ion may be provided in a separate document.
11.3.2. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
11.3.3. Final Report Signature
The final report coordinat ing invest igator or desi gnee will  sign the clinical  study  report for this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The sponsor’s responsible medical o fficer and statisticia n will  approve the final clinical study  
report for this study , confi rming that, to the best of his or her knowledge, the report accurately  
describes the conduct and results of the study .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 58
Abemaciclib (LY2835219)12. References
Blanchard J, Sawers SJ. The abso lute bioavailability  of caffeine in man. Eur J Clin 
Pharmacol. 1983;24(1):93 -98.
Cancer Therapy  Evaluat ion Program, Co mmo n Termino logy Criteria for Adverse Events, 
Versi on 5, DCTD, NCI, NIH, DHHS. 2009. Draft 2015.
Cushman M, Lim W, Zakai, NA.  Clinical Pract ice Guide on Ant ithromb otic Drug Dosing and 
Management of Antithro mbotic Drug -Associ ated Bl eeding Co mplications in Adults 
http://www.hematology .org/Clinicians/Guidelines -Qualit y/Quick -Ref/2869.aspx .February  
2014.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Fo rd R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (versio n 1.1). 
Eur J Cancer . 2009;45(2) 228 -
247.
EMA CPMP/EWP/560/95/Rev. 1 Corr. 2.  Guideline on the invest igation of drug interactions . 
2012.
Goh BC, Reddy  NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, 
Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD. An evaluat ion of the drug 
interaction potenti al of pazopanib, an oral  vascular endothelial growth factor receptor ty rosine 
kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in pat ients with advanced so lid 
tumors. Clin Pharmacol Ther . 2010; 88(5):652-659.
Imamura Y, Murayama N, Okudaira N, Kurihara A, Okazaki O, Izumi T, Inoue K, Yuasa H, 
Kusuhara H, Sugiyama Y. Predict ion of fluoroquinolone -induced elevat ion in serum creat inine 
levels: acase of drug -endogenous substance interaction invo lving the inhibit ion of renal 
secretion. C
lin Pharmacol Ther . 2011; 89(1):81 -88.
Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. 
Nat Rev Cancer . 2008;8(9):714 -724.
Lepist E -I, Zhang X, Hao J, Huang J, Kosaka A, Birkus G, Murray  BP, Bannister R, Cihlar T, 
Huang Y, Ray  AS. Contributi on of  the organi c anion transporter OAT2 to the renal active 
tubul ar secret ion of creatinine and mechanism for serum creat inine elevations caused by 
cobicistat. Kidney Int . 2014; 86:350 -357.
Ma JD, Nafziger AN, Villano SA, Gaedigk A, Bertino JS Jr. Maribavir pharmacokinetics and the 
effects of mult iple –dose m aribavi r on cy tochrom e P450 (CYP) 1A2, CYP 2C9, CYP 2C19, 
CYP 2D6, CYP 3A, N-acetyltransferase -2, and xanthine oxi dase in healt hy adults . Antimicrob 
Agents Chemother . 2006 ;50(4):1130-1135.
Midazol am 1 mg/mL Sol ution for Injection or Infusion. Summary  of Product Characteri stics. 
https://www.m edicines.org.uk/emc /medicine/25804. Accessed on December 12, 2014.
Midazol am Hydrochl oride Sy rup [Prescribing Informat ion]. Columbus, OH: R oxane 
Laboratories, Inc.; 2002. Revised September 2012.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 59
Abemaciclib (LY2835219)Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicit y 
and response criteria of the eastern cooperative oncology  group. Am J Clin Oncol . 
1982;5 (6):649-655.
Pharmaceut icals Medical  Devices Agency (PMDA) Draft Guideline on Drug Interactions . 2013. 
Guideline on Drug Interactions.
Rizzo JD, Brouwers M, Hurley  P, Sei denfeld J, Arcasoy  MO, Spivak JL, Bennett CL, Bohlius J, 
Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR. American Societ y of 
Hem atology/American Societ y of Clinical  Oncol ogy clinical  pract ice guideline updat e on the 
use of epoeti n and darbepoetin in adult patients with cancer. J Clin Oncol . 
2010;28(33):4996 -5010.
Schutzer KM, Svensson MK, Zetterstrand S, Eriksson UG, Wahlander K. Reversible elevat ions 
of serum  creat inine levels but no effect on glo merulus fil tration during treatment with the 
direct thrombin inhibitor AZD0837. Eur J Clin Pharmacol . 2010; 66(9):903 -910.
Smith TJ, Bohl ke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo  G, Wade JL, Wozniak AJ, Armitage JO. 
Reco mmendat ions for the Use of White Blood Cell Growth Factors: American Societ y of 
Clinical Onco logy Clinical  Practi ce Guideline Update. J Clin Onc 2015, 
http://jco.ascopubs.org/content/early/2015/07/08/JCO.2015 .62.3488.full. Accessed 
October 01, 2015.
Steinijans VW, Sauter R, Hauschke D, Diletti E, Schall R, Lu us HG, El ze M, Blume H, 
Hoffman C, Franke G et al . Ref erence tables for the intrasubject coefficient of variation in 
bioequivalence studies. Int J Clin Pharmacol Ther . 1995;33(8):42 7-430.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 60
Abemaciclib (LY2835219)Attachment 1. Protocol JPCB Study  Schedule
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 61
Abemaciclib (LY2835219)Study I3Y -MC-JPCB Study Schedule for Screening, and Periods 1 and 2
ScreenPeriod 1:  
Drug cocktailPeriod 2 (Cycle 1, Days 1 -12):  
Abemaciclib + drug cocktail  Early
discharge/
follow up a Study Day≤ -30 Baseline 
≤ -7 -1 1 2-7 1 2-7 8 9-12
Informed consent Xq
Medical history m X
Pregnancy test (if 
applicable)X X b
Urinalysis X X bX 
(Day 7)X
(Day  9)X
Renal markers Predosel Predose
8 hr24, 72 h
(Day s 9, 
11)
Hematology and 
serum chemistryX X bX 
(Day 7)Predose, 
8hj,r24, 72 h
(Day s 9, 
11)X
Physical exam & 
ECOG statusX X b,c Predose c24 h
(Day  9)cXc
Weight X X X X
Vital signs d X X bPredose, 2, 
8 h24 h
(Day  2)Predose, 
2, 8 h24 h
(Day  2)Predose, 
2, 8 h24 h
(Day  9)X
ABPM e 0-12 h 0-24 h(Day  5-8)e
0-24 h
ECG f X XPredose, 2, 
8 h24 h
(Day  2)PredosePredose, 
2, 8 h24 h
(Day  9)X
INR (PD and 
safety )nPredose, 
8 hr24, 48, 
72, 96 hPredose, 
8 hr24, 48, 
72, 96 h
AEs & con meds o Throughout study
Bowel habit/dosing 
Patient diaryDaily  from Baseline through the end of Cycle 2 (Period 4)
Bowel habit 
Patient outcomesX Predose Predose Day7
Abemaciclib Q12H Day 1kDay 2-7 Day 8kDay 9-12
Drug cocktail 
administrationX Xs
PK sampling 
abemaciclib gPredose
(Day  7)PredosePredose 
(Day  9)
PK sampling 
caffeine g Predose, 
0.5, 1, 2, 3, 
4, 6, 8, 
12 h24, 48 hPredose, 
0.5, 1, 2, 
3, 4, 6, 8, 
12 h 24, 48 h
PK sampling 
warfarin g,pPredose, 1, 
2, 4, 6, 8, 
10 h24, 48, 
72, 96 hPredose, 
1, 2, 4, 6, 
8, 10 h24, 48, 
72, 96 h
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 62
Abemaciclib (LY2835219)ScreenPeriod 1:  
Drug cocktailPeriod 2 (Cycle 1, Days 1 -12):  
Abemaciclib + drug cocktail  Early
discharge/
follow up a Study Day≤ -30 Baseline 
≤ -7 -1 1 2-7 1 2-7 8 9-12
PK sampling 
dextromethorphan gPredose, 
1, 2, 4, 6, 
8, 10 h24, 48, 
72 hPredose, 
1, 2, 4, 6, 
8, 10 h24, 48, 
72 h
PK sampling 
midazolam gPredose,
0.5, 1, 2, 3, 
4, 6, 8,12 h24 hPredose, 
0.5, 1, 2, 
3, 4, 6, 8, 
12 h 24 h
Pharmacogen etic
sampleXh
CYP genotyping 
sampleXh
Tumor assessment Xi
Abbreviations:  ABPM = ambulatory blood pressure monitoring; AE = adverse event; con meds = concomitant 
medications; ECG = electrocardiogram; ECOG =Eastern Cooperative Oncology Group; exam = examination; 
INR = international normalized ratio; h = hour(s); PD = pharmacodynamic; PK=pharmacokinetic ; 
Q12H =every 12 hours .
aPatients who discontinue early from the study should return for a discharge visit after a washout period of at least 
10 days from the last abemaciclib dose to perform the same assessments as required at the follow -up visit.  If a 
patient completes Periods 1 an d 2, it is expected that the patient will enter Period 3.  If patients do not enter 
Period 3 after completing required serial blood sampling in Period 2, patients will have a discharge visit after a 
washout period of at least 10 days from the last abemacic libdose.
bSerum pregnancy test should be repeated if >3 days from Day 1.
cDirected physical examination. Directed examination on Day 9 to include assessment for evidence of bleeding.
dVital signs will be collected before any blood samples at the specified time.  Supine ,semi-recumbent , or sitting
blood pressure, heart rate, and body temperature will be obtained.  Vital signs can be omitted, if already taken as 
part of routine standard of care on the day informed consent istaken.
eAn ABPM device will be fitted for a 12 -hour acclimation period between Days -7 to -2 in Period 1.   Following 
the acclimation period, b aseline ABPM assessments will be performed over a 24 -hour period between Day -2 
and dosing on Day 1 in Period 1.  In Period 2, ABPM asses sments will be performed over a 24 -hour period once 
between Days 5 to 8 ; no other procedures should be performed during this ABPM assessment .
fPatients must be supine or semi -recumbent for approximately 5 to 10 minutes before ECG collection and remain 
supine or semi -recumbent but awake during ECG collection.  ECGs should be collected prior to any blood draws 
scheduled at the same time point, and ECGs should preferably be collected before (rather than just after) meals.  
ECGs may be obtained at additional times, whe n deemed clinically necessary.
gAll sample times are relative to the administration of the drug cocktail, except for the trough abemaciclib 
samples.  PK sample collection times are nominal; actual times should be recorded.  Separate blood samples, 
2mL each, will be collected for the drug concentration measurements of abemaciclib , caffeine, 
dextromethorphan, midazolam , and warfarin.   
hObtain o nly once after enrollment and elig ibility is confirmed. This sample can be taken during the baseline visit 
or at Predose Period 1, Day 1 once eligibility is confirmed.   
iRadiological tumor assessment can be omitted if prior scan is within approximately 4 weeks.  See Section 8.3for 
additional information.
jSerum creatinine only.
kThe first dose of abemaciclib on Day 1 should take place at the study site.  Patients will report to the study  site on 
Day 8 and will be coadministered abemaciclib and the drug cocktail in the morning.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 63
Abemaciclib (LY2835219)lIncludes 2 blood samples collected for central laboratory assessment of renal markers in serum.
mTo include the recording of the use of alcohol, tobacc o, nicotine replacement therapy ,and caffeine.
nIf warfarin is not dosed in Period 2 cocktail, the INR sampling throughout Period 2 is not required; however, the 
INR may be assessed at the investigator’s discretion for safety purposes.
oPatients will be provided with a paper diary in which to record the start and stop times of all AEs ,new 
concomitant medications and medications taken as needed from the baseline visit until the end of Period 2.
pIf warfarin is not dosed in Period 2 cocktail, the warfarin PK sampling throughout Period 2 is not required.
qDate and time of informed consent will be recorded.
rThe 8-hour postdose sample may be drawn within ±2 hours (thus, at the 6 hour postdose or 10 hour postdose 
time point at the discretion of the site) .  The actual time of collection must be recorded. 
sCocktail may be administered without warfarin in Period 2 if patient has an INR >2 after receiving warfarin in 
Period 1 (Section 7.2.1 ).
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 64
Abemaciclib (LY2835219)Study I3Y -MC-JPCB Study Schedule for Periods 3 and 4
Study DayPeriod 3
Cycle 1, Days 13 -28Period 4a
Cycle 2Follow -upb
Directed physical exam & 
ECOG statusX X
Vital signs c& weight XcX
Renal biomarkers Days 1, 14f, 28
Bowel habit/dosing 
Patient diaryX
(Daily )Daily
(Day s 1 through 28 )g
Bowel habit 
Patient outcomesDays 14, 21 Days 1, 7, 14, 21, 28d
Hematology &serum 
chemistryDays 1, 14f, 28 X
AEs & con meds X X X
Abemaciclib Q12H X Daily
Tumo r assessment XeX
Abbreviations:  AE = adverse event; con meds = concomitant medications; ECOG =Eastern Cooperative Oncology 
Group; exam = examination; Q12H = ever y 12 hours.
aPatients will be required to return to the site on Day 1 of each 28 -day cycle (±4 days).
bFor patients who will not participate in the safety extension, the follow -up assessment will occur approximately 
10 days after the end of the second cycle.
cVital signs will be collected before any blood samples at the specified time. Supine ,semi-recumbent , or sitting
blood pressure, heart rate, and temperature will be obtained.
dCycle 2, Day 28 patient outcomes may be completed before any procedures on Day 1 of C ycle 3.
eRadiological tumor assessment should be performed on Day 28 ( ±14 days).
fCycle 2, Day  14 labs (+/ -2 days) .
gPatient diary will extend through the end of Period 4 if longer than 28 days .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 65
Abemaciclib (LY2835219)Study I3Y -MC-JPCB Study Schedule for Safety Extension Phase
Study DaySafety extension: 
abemaciclib aFollow -upb
Directed physical exam & 
ECOG statusX X
Vital signs c& weight X X
ECG e X
Hematology, serum 
chemistry , & urinalysisX X
AEs & con meds X X
Abemaciclib 
administration X
Tumo r assessment Xd X
Abbreviations:  AE = adverse event; con meds = concomitant medications; ECG = electrocardiogram; 
ECOG = Eastern Cooperative Oncology Group; exam = examination.
aPatients will be required to return to the site on Day 1 of each 28 -day cycle (±4 days).
bFor patients participating in the safety extension, the follow -up assessment will occur approximately 10 days 
after the planned end of the last cycle.
cVital signs will be collected before any blood samples at the specified time.  Supine ,semi-recumbent , or sitting
blood pressure, heart rate, and temperature will be obtained.
dRadiological tumor assessment should be performed on Day 28 (±14 days).  Imaging studies should be 
performed at the end of ever y 2 cycles (approximately every 4 to 8 weeks) up until 30 days after final 
abemaciclib dose, when another therapy is initiated, when there is disease progression, or w hen the patient dies
per standard of care until objective progression is observed based on the efficacy measurement criteria described 
in Section 8.3.  If a patient is discontinued from the study, repeat radiology may be omitted if progressive disease 
can be documented quantitatively with clinical measurements.
ePatients must be supine or semi -recumbent for approximately 5 to 10 minutes before ECG collection and remain 
supine or semi -recumbent but awake during ECG collection.  ECGs should be collected prior to any blood draws 
scheduled at the same time point, and ECGs sho uld preferably be collected before (rather than just after) meals.  
ECGs may be obtained at additional times, when deemed clinically necessary.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 66
Abemaciclib (LY2835219)Attachment 2. Protocol JPCB Clinical Laboratory  Tests
Clinical Laboratory Tests
HematologyaClinical Chemistrya
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Total and direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils Alanine aminotransferase 
Lymphocy tes Aspartate aminotransferase 
Monocytes Gamma -glutamyl transpeptidase
Eosinophils Blood urea nitrogen 
Basophils Creatinine
Platelets Uric acid
Calcium
Coagulation parametersa, fGlucose, random
aPTT Albumin
PT Total protein
INR Magnesium
Phospho rus
Chloride
UrinalysisaLactate dehydrogenase
Specific gravity Osmolality
pH
Protein Renal Biomarkersb
Glucose Cystatin-C c
Ketones NGAL c,d
Blood KIM -1 d
Urine leukocyte esterase Creatinine c, d
Serum Urine Pregnancy Test
(females of child bearing potential only)
CYP2C9, CYP2D6, CYP3A 4, and CYP3A5
genotypinge
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 67
Abemaciclib (LY2835219)Abbreviations:  RBC = red blood cells; WBC = white blood cells; aPTT = activated partial thromboplastin time, 
CYP = cytochrome P450; INR = international normalized ratio; KIM -1 = kidney injury molecule -1; 
NGAL =neutrophil gelatinase -associated lipocalin; PT = prothrombin time.
aPerformed by local laboratory for safety management and the central laboratory for reporting purposes at all 
timepoint, except screening when only a local laboratory will be used .
bPerformed by a central laboratory (notperformed at screening ).
cVenous blood samples will be collected for serum tests.
dUrine samples (at least 5 mL and up to 120 mL) will be collected and tested.
ePerformed at baseline only
fCoagulation parameters need not be measured in Period 2 if war farin is not included in the Period 2 drug 
cocktail .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 68
Abemaciclib (LY2835219)Attachment 3. Protocol JPCB Hepatic Monitoring Tests for 
Treatment -Emergent Abnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly CRP/CP or designee.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin time
WBC Prothrombin time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Anti -smooth muscle antibody a
CPK 
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssayed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 69
Abemaciclib (LY2835219)Attachment 4. Protocol JPCB Recommendations for 
Reporting Serious Adverse Events
Recommendations for Reporting Serious Adverse Event s
When contacting Lilly  to report a SAE, pl ease have the fo llowing inform ation available:
Patient Demographics
patient identificat ion (number), sex, date of birth, origin, height, and weight
Study Identification
full trial protocol number, invest igato r's name, investigator’s number
Study Drug
drug code or drug name, unit dose, total daily dose, frequency, route, start dose, 
cycle details, start date and last dose date (if applicable)
Adverse Event
descript ion, date of onset, severit y, treatm ent (in cluding hospitalizat ion), acti on 
taken wi th respect to study  drug, clinical significance, test and procedure results 
(if applicable)
Relationship to Study Drug & Protocol Procedures
Concomitant Drug Therapy
indicat ion, total  daily dose, duration of treatm ent, start date, acti on taken
In Case of Death
cause, autopsy  finding (if available), date, relat ionship to study  drug and protocol 
procedures.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 70
Abemaciclib (LY2835219)Attachment 5. Protocol JPCB Eastern Cooperative Oncology  
Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status
Activity Status Description
0 Fully  active, able to carry on all pre -disease performance without 
restriction
1 Restricted in physically strenuous activity but ambulatory and able 
to carry  out performance of a light or sedentary nature, for example, 
light housework, office work
2 Ambulatory and capable of all self -care but unable to carry out any 
work activities.  Up and about more than 50% of waking hours
3 Capable of only limited self -care, confined to bed or chair more than 
50% of waking hours
4 Completely disabled.  Cannot carry on any self -care.  Totally 
confined to bed or chair
5 Dead
Source:  Oken et al. 1982.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 71
Abemaciclib (LY2835219)Attachment 6. Protocol JPCB Sampling Summary
This table summarizes the maximum number of samples, vo lumes forall sampling, and tests 
during the study .  The summary  below provi des estimates. More samples could be required in 
the case of retests, addit ional health monitoring (if needed), or for patients continuing treatment 
beyo nd the protocol -specified number of cycles in the study .  Fewer samples m ay actually be 
taken (for example, patients who discontinue from the study ).
Protocol I3Y -MC-JPCB Sampling Summary (Periods 1 to 4)
PurposeMaximum Amount 
per Sample (mL)Maximum 
Number 
SamplesMaximum 
Total Amount
(mL)
Screening tests (local lab) a 7.5 1 7.5
Serum pregnancy test, if 
applicable b5 2 10
Clinical laboratory tests (local 
lab) a7.5 10 75
Clinical laboratory tests 
(central lab) a15 10 150
Renal markers 5 8 40
Safety and PD INR 2 12 24
Drug concentrations:
Caffeine 
Warfarin
Dextromethorphan
Midazolam
Abemaciclib2
2
2
2
222
22
20
20
344
44
40
40
6
Pharmacogenetic sample 10 1 10
CYP genotyping sample 10 1 10
Catheter flush 1 18 18
Additional PK sampling, if 
applicable 3 5 15
Provision for unscheduled 
labs- - 30
Total 563.5
Total rounded for clinical 
purposes570
Abbreviation:  INR = international normalized ratio; PD = pharmacodynamic; PK = pharmacokinetic.
aAdditional samples may be drawn if needed for safety purposes.
bBlood volume may vary.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 72
Abemaciclib (LY2835219)Attachment 7. Protocol A mendment I3Y-MC-JPCB( d) 
Summary  Effects of Multiple Doses of A bemaciclib on the 
Pharmacokinetics of Cy tochrome P450 (CYP) 1A 2, CYP2C9, 
CYP2D6, and CYP3A  Substrates (Caffeine, Warfarin, 
Dextromethorphan, and Mid azolam) in Cancer Patients
Overview
Protocol  I3Y-MC-JPCB [Effects of Mult iple Doses of Abemaciclib on the Pharmacokinet ics of 
Cytochrom e P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, 
Dextrom ethorphan, and Midazo lam) in Cancer Patients] has been amended.  The new protocol is 
indicated by  Amendment ( d) and will be used to conduct the study in place of any preceding 
versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
In order to explain how AEs and concomitant medicat ions are to be recorded 
during the study , inform ation regarding a paper diary  to be issued to patients
hasbeen added.  
As INR i s measured in order to monitor any  adverse ant icoagulant effects of 
warfarin, t he protocol has been revised to allow any subject with INR >2 after 
the first dose of warfarin to receive abemaciclib once their INR has stabilized 
or returned to baseline, and for the patient to receive drug cocktail without 
warfarin in Period 2.  Flexibi lity has been added regarding replacement of 
such pati
ents to allow assessment of the impact of the missing warfarin PK 
data on the overall analysis ,prior to the decision being made to replace the 
subject.  
The abemaciclib dose adjust ment criteria have b een amended and clarification 
given to the requirement for dose reduction fo llowing administration of white 
blood cell growth factors only.
A ±2 hour window of flexibilit y has been allo wed, if necessary , around the 
8hour postdose renal marker, hematology  and serum  chemistry , and INR 
sampling t ime point, in order to ensure samples can be analyzed on the day 
they are drawn .  
Minor clarificat ions have been added and minor typographical and formatting edits 
were m ade throughout the document for clarit y and co nsistency.  
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 73
Abemaciclib (LY2835219)Revised Protocol Sections
Note: All deletions have been ident ified by strikethroughs .
All additions have been ident ified by the use of underscore .
6.1.1. Inclusion Criteria
Patients m ay be included in the study  if they  meet all  of the f ollowing cri teria during screening 
prior to first dose of study  drug enrollment .
6.1.2. Exclusion Criteria
[13] Have received treatment within 28 days o f the init ial dose of study drug with 
an invest igational product (non-cancer -related therapi es)or non -approved use 
of a drug or device (other than the study  drug used in this study ) or are 
concurrent ly enro lled in any other ty pe of m edical  research j udged not to be 
scientifically or medically co mpatible wit h this study .
6.2. Summary of Study Design
This will be an open -label, 4 -period, fixed- sequence study , followed by a safet y extensio n phase, 
in patients with advanced and/or metastatic cancer.
The drug cocktail o f 100 m g caffeine, 10 mg warfarin , 30 m g dextrom ethorphan, and 0.2 mg 
midazo lam will be administered orally  as a single dose on 2 occasions:  Day  1 in Peri od 1, and in 
combinat ion with abemaciclib on Day  8 of Period 2, after 7 day s of 200 m g abemaciclib Q12H 
dosing.  After complet ing Peri od 2, pati ents will  continue to receive abemaciclib at a dose of 
200mg Q12H (or a modified dose) through the end of Periods 3 and 4, in 28 -day cycles, and 
then may cont inue in a safet y extensio n phase unt il discont inuat ion criteria are m et.  Pati ents 
who do not complete dosing and PK sampling through Period 2 may be replaced.
Patients will  be provi ded wi th an electronic diary  from the baseline visit through the end of 
Cycle 2 to record the time and date of abemaciclib administration, any const ipation or
anti-diarrhea medicat ions taken, and bowel habits and any changes.
6.2.1 .Safety Extension Phase
Patients who parti cipate in the safet y extensio n phase of the study  will receive an abemaciclib 
dose of 200 mg Q12H (or modified dose as applicable) on a 28- day cycle until discont inuat ion 
criteria are met (eg, disease progression, death, or unacceptable toxicit y (Section 6.3).  If 
interrupti ons in dosing are required for significant periods of time (> 14 days) continuat ion of 
treatm ent wi th abemaciclib may  be con sidered if fel t to be in the best interest of the patient’s 
care and upon discussio n with the m edical mo nitor.  Tum or re -staging may be allowed and will 
be docum ented when necessary .
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 74
Abemaciclib (LY2835219)7.2.1. Dosing Schedule
Period 2
On Days 1 to 12, 4 × 50- mg capsules of abemaciclib will be administered orally  in the m orning 
and evening with approximately  240 mL of room temperature water, in a sitting posit ion.  
Abemaciclib should be taken at approximately the same time each day .  On Day 8, abemaciclib 
will be coadminister ed wi th10 m L of 20
-mg/mL caffeine citrate solut ion (100 mg caffeine), 
2 × 5- mgtablets of  warf arin, 2 × 15-mgliquid gel capsules o f dextrom ethorphan, and 0.1 mL of 
2-mg/mL midazo lam syrup with approximately 240 mL of room temperature water, in a sitting 
position.  On Day  8 (coadministrati on wi th the drug cocktail), patients should not consume food 
beginning 1 hour before and ending 1 hour after taking study  drugs .  
If a patient has an INR >2 after the first dose of warfarin, the patient may receive the d rug 
cocktail wit hout warfarin in Period 2 and receive abemaciclib once their INR has stabilized or 
returned to baseline.  
If a patient misses or vomits a dose of abemaciclib , that dose should be omitted (see Section 7.6
for com pliance).  Pati ents will  be asked to take each dose of study  drug wi thin +/ -2 hours of the 
planned dose time or consider the dose a missed dose. 
Periods 3, 4 and Safety Extension Phase  
From  Cycle 1, Peri od 3 and on Day s 1 to 28 in each cycle (Cycle 2 onwards), 4 × 50- mg capsule 
of abemaciclib will be taken orally in the morning and evening.  A bemaciclib should be taken at 
approximately  the same t ime each day.  
A delay  of 7 days in the start of a cy cle (Day  1) for j ustifiable reasons (for example, inclement 
weather, holidays, or weekends) other than toxicit y will be permitted and does not constitute a 
protocol  violation.  A delay of 14 days in the start of a cycle (Day  1) to allow for recovery  from 
toxicity will be permi tted and does not consti tute a protocol  violation.  
A longer delay  may be 
allowed for the start of Cy cle 1 (or Peri od 2), if necessary.  In cases where Cycle 1 (abemaciclib 
dosing) is significant ly delayed fro m tumor staging during screening, baseline staging may be 
repeated.  If there is any quest ion, thi s may  be discussed with the study  medical  monitor.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 75
Abemaciclib (LY2835219)Table JPCB.7.1. Toxicity Dose Adjustments and Delays of Abemaciclib for 
Study JPCB
Toxicity Type Toxicity Profile and Severity Dose Suspension Dose Reduction
Hematologic Toxicity
Neutropenia/thrombocytopenia
Section 7.2.2.1Grade 3 which lasts 7 days Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2.Dose MAY be reduced 
by 1 dose level -
investigator’s discretion.
Hematologic Toxicity
Neutropenia/thrombocytopenia
Section 7.2. 12.1Recurrent Grade 3 (on later cycle) 
which lasts 7 daysDose MUST be suspended 
until toxicity resolves to at 
least Grade 2.Dose MUST MAY be 
reduced by 1 dose level –
investigator’s discretion .
Hematologic Toxicity 
Neutropenia/thrombocytopenia
Section 7.2. 12.1Grade 4 which lasts 3 days Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2.Dose MUST be reduced 
by 1 dose level.
Hematologic toxicity:  Patient 
requires administration of 
white blood cell growth 
factors
Section 7.2.12.1Regardless of severity
(Growth factors use according to 
ASCO Guidelines)Dose MUST be suspended 
for at least 48 hours after 
the last dose of white blood 
cell growth factors was 
administered and until 
toxicity resolves to at least 
Grade 2.Dose MUST be reduced 
by 1 dose level unless 
already  performed for 
incidence of toxicity that 
lead to the use of white 
blood cell growth factor.
Nonhematologic Toxicity 
(except diarrhea)
Section 7.2.2.2 .1Persistent or recurrent Grade 2 that 
does not resolve with maximal 
supportive measures within 7 days 
to baseline or Grade 1Dose MAY be suspended 
until toxicity resolves to 
either baseline or Grade 1.Dose MAY be reduced 
by 1 dose level -
investigator's discretion.
Nonhematologic Toxicity 
Section 7.2.2.2. 1Grade 3 or 4 Dose MUST be suspended 
until toxicity resolves to 
either baseline or Grade 1.Dose MUST be reduced 
by 1 dose level.
Diarrhea
Section 7.2.2.2. 2Requires hospitalization or Grade 3 
or 4Dose MUST be suspended 
until toxicity resolves to at 
least Grade 1.Dose MUST be reduced 
by 1 dose level.
Diarrhea
Section 7.2.2.2 .2Persistent or recurrent Grade 2 that 
does not resolve with maximal 
supportive measures within 
24hours to at least Grade 1Dose SHOULD be 
suspended until toxicity 
resolves to at least Grade 1.Dose MAY be reduced 
by 1 dose level -
investigator's discretion.
Diarrhea
Section 7.2.2.2. 2Diarrhea recurs despite maximal 
supportive measures after resuming 
same dose level after initial 
Grade 2diarrheaDose MUST be suspended 
until toxicity resolves to at 
least Grade 1.Dose MUST be reduced 
by 1 dose level.
Abbreviation:  ASCO = American Society of Clinical Oncology.
Note:  MAY =per the investigator’s clinical judgment; SHOULD =not mandatory but highly recommended; 
MUST =mandato ry.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 76
Abemaciclib (LY2835219)7.2.2.1. Hematologic Toxicity
If a patient experiences Grade 4 hematol ogic toxi cityneutropeni a/thrombocy topeni a, which l asts 
3 day s, then dosing must be suspended (unt il the toxicit y resolves to at l east Grade 2) and the 
dose of abemaciclib must be reduced as outlined in Table JPCB. 7.2.
If a patient experiences Grade 3 hematol ogic toxicityneutropeni a/thrombocy topeni a, 
which l asts 
7 day s,then dosing must be suspended (unt il the toxicit y resolves to at l east Grade 2) and the 
dose of abemaciclib may be reduced by 1 dose l evel.  If the pati ent experiences a recurrent 
episode of Grade 3 hematol ogic toxi cityneutropenia/th rombocy topenia in a later cy cle, which 
lasts 7 days, then dosing must be suspended (until the toxicit y resolves to at least Grade 2 and the 
dose of abemaciclib must may be reduced by 1 dose l evel.
If a patient requires administration of white blood cell growth factors, the dose of study  drug 
must be suspended for at least 48 hours after the last dose of white blood cell growth factors was 
administered and unt il toxicit y resolves to at least Grade 2, then reduced by 1 dose l evel, if a 
dose reduction for the specific event necessitat ing the use of the white blood cell  growth factors 
has not al ready  occurred.
Before the start of each cycle, hematologic toxicit y possibly related to abemaciclib must resolve 
to at l east Grade 2.
7.5. Concomitant Therapy
No other chemotherapy , radi otherapy , immunotherapy , cancer -related horm one therapy , or 
experimental drugs will be permi tted while the patients are on this study , except for those 
described in Inclusion Criterion [7] in Section 6.1.1 .
The need for radiotherapy  will be cause for early discontinuat ion from the study , with the 
exception of palliat ive radiotherapy, which i s permitted if not being utilized for disease 
progression .  In addit ion, any disease progression requiring other forms of specific antitumor 
therapy  will also necessitate early  discontinuati on from the study .
Appropriate documentation for all forms of prem edications, supportive care, and concomitant 
medicat ions m ust be captured on the case report form (CRF).   Patients will be provided with a 
paper diary  in which to record the start and stop times of new conco mitant medicat ions and 
medicat ions taken as n eeded from  the baseline visit until the end of Period 2.
7.5.1.3. Growth Factors
Patients shoul d receive full supportive care during the trial.  Growth factors should not be 
administered to enable a pat ient to satisfy study  inclusion cri teria.  Growth fact ors m ay be used 
in accordance wit h American Societ y of Clinical  Oncol ogy (ASCO) gui delines (Smit h et al . 
2015) if clinically indicated.  Dosing of study  drug m ust be suspended if the administration of 
white blood cell growth factors is required and must no t be recommenced wit hin 48 hours of the 
last dose of growth factors having been administered. Following the administration of white 
blood cell growth factors, the dose of study  drug must be reduced by  one dose level , if a dose 
reducti on for the specific e vent necessitat ing the use of the growth factors has not already 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 77
Abemaciclib (LY2835219)occurred.  Before the start of each cycle, hematologic toxicit y must resolve to either baseline or 
at least Grade 2.
Erythroid-stimulat ing agents (ESAs, including eryt hropoi etin and darbepoet in) or transfusio ns 
shoul d not be administered to enable a pat ient to satisfy study  inclusio n criteria.  Both ESAs and 
transfusio n therapy  may be used in accordance with American Societ y of Hematol ogy and 
ASCO guidelines (Rizzo et al. 2010), if clinically indicated. If a patient requires administration 
of blood cell growth factors, the dose of study  drug mustbe reduced by one dose level, if a dose 
reducti on for the specific event necessitat ing the use of the growth factors has not already 
occurred.  Before the start of each cycle, hematologic toxicit y must resolve to either baseline or 
at least Grade 2.
7.6 Treatment Compliance
If a patient misses 2 or more of the planned doses of abemaciclib within 3 consecut ive days prior 
to the drug cocktail dose in Period 2, the patient will need to be replaced, or dosing with the drug 
cocktail may  be delayed to allow for adequate exposure.  Delay should only occur on a 
case-by-case basis fo llowing discuss ion and agreement with the Lilly CRP/CP or designee.  
Likewise, if dose reduction is required to less than 150mg Q12H or if dose interruptions or 
omissio ns are deemed necessary  during Peri od 2 for greater than 43consecut ive doses at any 
time, the patient may recommence dosing of abemaciclib wit h delay o f Period 2 drug cocktail 
dosing so that abemaciclib steady  state i s achieved ( minimum 5-7 days) will need to be replaced .  
8.1.2. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.  A clinical study  AE is any untoward medical occurrence 
in a pati ent or clinical invest igation subject administered a pharmaceut ical product and which 
does not necessarily  have a causal  relati onship wi th this treatm ent.  An AE can therefore be any  
unfavorable and unintended sign (including an abnormal laboratory  finding), symptom, or 
disease tem porally associ ated wi th the use of m edicinal (invest igational) product, whether or not 
related to the medicinal (invest igational) product.  Any clinically significant findings fro m labs, 
vital sign m easurements, and so on that occur should also be reported to Lilly  or its designee as 
an AE.  Lack of drug effect is not an AE in clinical studi es because the purpose of the clinical 
study  is to establish drug effect.
The invest igator, monitor, and sponsor will review the collected data regularly for evidence of 
AEs.  All pat ients will be assessed routinely for AEs as outlined in the Study  Schedul e.  Patients 
will be provided with a paper diary  in which to record the start and stop times of all AEs 
experienced fro m the baseline visit unt il the end of Period 2.
8.1.3.1 .Vital Signs
Blood pressure, pulse rate, and body  temperature will  be measured as specified in the Study  
Schedule and as clinically  indicated ( Attachment 1 ).
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 78
Abemaciclib (LY2835219)Blood pressure and pulse rate should be measured after at least 5 minutes supine or,
semi-recumbent , or si tting; the posit ion shoul d be recorded.
8.1.3.3. Electrocardiograms
For e ach patient, a 12 -lead di gital ECG will  be collected according to the Study  Schedule 
(Attachm ent 1 ).  Patients must be supine or semi-recumbent for approximately 5 to 10 minutes 
before ECG collect ion and remain supine or semi -recumbent but awake during ECG collect ion.  
8.1.3.4.2 . Patient Diary
An electronic patient di ary to collect date and time of bowel movements, a Bristol Stool Chart, 
and drug administration will be completed daily by the patient, starting at baseline and required 
through end of Period 2.  Patients participat ing in Period 3 and 4 should continue complet ing 
diary entri es through end of Period 4.   Patients will also receive a paper diary in which to record 
the start and stop times of all AEs, new conco mitant m edicat ions and medicat ions tak en as 
needed from the baseline visit unt il the end of Period 2.
8.2.2.2 .Pharmacodynamic Samples
At the visit s and t imes specified in the Study Schedule ( Attachment 1 ), venous blood samples 
will be co llected to determine INR (see Attachment for the blood sampling summary).  Analysis 
of PT or INR will be performed by local labs.  Local labs for PT or INR will be co llected for 
patient management and PD analyses. 
Guidanc e Regarding Elevation of the INR
Patients will  receive a single dose of warfarin (10 mg) as part of the drug cocktail in Period 1 and 
Period 2:
Period 1:  If a patient has an INR >2 after the first dose of warfarin, the patient should not 
receive warfarin again in the drug cocktail in Period 2, but may  be all owed to enter the 
study Period 2 and receive abemaciclib once their INR has stabilized or returned to 
baseline.  The patient should may be repl aced.
Period 2:  For any  patient found to have an INR 4 after the administration of warfarin in 
Period 2, further abemaciclib dosing should be held until the INR stabilizes or returns to 
baseline (refer to Section 7.2.2 ).
9.2.1 Case Report Form
An electronic data capture sy stem  will be used in this study .  The si temaintains a separate source 
for the data entered by  the si te into the sponsor -provided electronic data capture system.
Any data for which paper documentation provided by the patient will serve as the source 
docum ent will be i dentified and documented by  each site in that site’s study  file.  Paper 
docum entati on provi ded by  the pat ient may include, for example, a paper diary  to collect 
patient-reported outcome measures (for example, a rating scale), a daily dosing schedule or an 
event di ary. 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 79
Abemaciclib (LY2835219)If informat ion reported during an office visit differs from that recorded in the paper diaries, the 
source data (collected during patient interview) will supersede for purposes of collection in the 
CRF.
For data handled by a data management third-party organization (TPO), CRF data and some or 
all data that are related will be managed and stored electronically in the TPO system.   
Subsequent to the final database lock, validated data will be transferred to the Lilly  data 
warehouse, using standard Lilly file transfer processe s.
11.1.Informed Consent
The invest igator is responsible for ensuring that the patient understands the potential risks and 
benefits of part icipating in the study, including answering any questions the patient may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the pati ent’s willingness to continue his or her participat ion in the study  in a timely manner.
The ICF will be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in simple terms before the patient is entered into the study  and to document that the 
patient is sat isfied with his or her understanding o f the potential risks and benefits o f 
participat ing in the study and desires to participate in the study.
The invest igator is ult imately responsible for ensuring that informed consent is given by each 
patient or l egal representati ve before the study  is started.  Thi s includes obtaining the appropriate 
signatures , time of consent, and dates on the ICF prior to the perfor mance of any protocol 
procedures and prior to the administration of study drug. 
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 80
Abemaciclib (LY2835219)Study I3Y -MC-JPCB Study Schedule for Screening, and Periods 1 and 2
ScreenPeriod 1:  
Drug cocktailPeriod 2 (Cycle 1, Days 1 -12):  
Abemaciclib + drug cocktail  Early
discharge/
follow up a Study Day≤ -30 Baseline 
≤ -7 -1 1 2-7 1 2-7 8 9-12
Informed consent Xq
Medical history m X
Pregnancy test (if 
applicable)X X b
Urinalysis X X bX 
(Day 7)X
(Day  9)X
Renal markers Predosel Predose
8 hr24, 72 h 
(Day s 9, 
11)
Hematology and 
serum chemistryX X bX 
(Day 7)Predose, 
8hj,r24, 72 h
(Day s 9, 
11)X
Physical exam & 
ECOG statusX X b,c Predose c24 h
(Day  9)cXc
Weight X X X X
Vital signs d X X bPredose, 2, 
8 h24 h
(Day  2)Predose, 
2, 8 h24 h
(Day  2)Predose, 
2, 8 h24 h
(Day  9)X
ABPM e 0-12 h 0-24 h(Day  5-8)e
0-24 h
ECG f X XPredose, 2, 
8 h24 h
(Day  2)PredosePredose, 
2, 8 h24 h
(Day  9)X
INR (PD and 
safety )nPredose, 
8 hr24, 48, 
72, 96 hPredose, 
8 hr24, 48, 
72, 96 h
AEs & con meds o Throughout study
Bowel habit/dosing 
Patient diaryDaily  from Baseline through the end of Cycle 2 (Period 4)
Bowel habit 
Patient outcomesX Predose Predose Day7
Abemaciclib Q12H Day 1kDay 2-7 Day 8kDay 9-12
Drug cocktail 
administrationX Xs
PK sampling 
abemaciclib gPredose
(Day  7)PredosePredose 
(Day  9)
PK sampling 
caffeine g Predose, 
0.5, 1, 2, 3, 
4, 6, 8, 
12 h24, 48 hPredose, 
0.5, 1, 2, 
3, 4, 6, 8, 
12 h 24,48 h
PK sampling 
warfarin g,pPredose, 1, 
2, 4, 6, 8, 
10 h24, 48, 
72, 96 hPredose, 
1, 2, 4, 6, 
8, 10 h24, 48, 
72, 96 h
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 81
Abemaciclib (LY2835219)ScreenPeriod 1:  
Drug cocktailPeriod 2 (Cycle 1, Days 1 -12):  
Abemaciclib + drug cocktail  Early
discharge/
follow up a Study Day≤ -30 Baseline 
≤ -7 -1 1 2-7 1 2-7 8 9-12
PK sampling 
dextromethorphan gPredose, 
1, 2, 4, 6, 
8, 10 h24, 48, 
72 hPredose, 
1, 2, 4, 6, 
8, 10 h24, 48, 
72 h
PK sampling 
midazolam gPredose, 
0.5, 1, 2, 3, 
4, 6, 8,12 h24 hPredose, 
0.5, 1, 2, 
3, 4, 6, 8, 
12 h 24 h
Pharmacogenetic 
sampleXh
CYP genotyping 
sampleXh
Tumor assessment Xi
Abbreviations:  ABPM = ambulatory blood pressure monitoring; AE = adverse event; con meds = concomitant 
medications; ECG = electrocardiogram; ECOG =Eastern Cooperative Oncology Group; exam = examination; 
INR = international normalized ratio; h = hour(s); PD = pharmacodynamic; PK =pharmac okinetic; 
Q12H =every 12 hours.
aPatients who discontinue early from the study should return for a discharge visit after a washout period of at least 
10 days from the last abemaciclib dose to perform the same assessments as required at the follow -up visi t.  If a 
patient completes Periods 1 and 2, it is expected that the patient will enter Period 3.  If patients do not enter 
Period 3 after completing required serial blood sampling in Period 2, patients will have a discharge visit after a 
washout period of at least 10 days from the last abemaciclib dose.
bSerum pregnancy test should be repeated if >3 days from Day 1.
cDirected physical examination.   Directed examination on Day 9 to include assessment for evidence of bleeding.
dVital signs will be collected before any blood samples at the specified time.  Supine or,semi-recumbent , or 
sitting blood pressure, heart rate, and body temperature will be obtained.   Vital signs can be omitted, if already 
taken as part of routine standard of care on the day informed consent is taken.
eAn ABPM device will be fitted for a 12- hour acclimation period between Days -7 to -2 in Period 1.  Following 
the acclimation period, baseline ABPM assessments will be performed over a 24 -hour period between Day -2 
and dosing o n Day  1 in Period 1.  In Period 2, ABPM assessments will be performed over a 24 -hour period once 
between Days 5 to 8; no other procedures should be performed during this ABPM assessment.
fPatients must be supine or semi -recumbent for approximately 5 to 10 minutes before ECG collection and remain 
supine or semi -recumbent but awake during ECG collection.  ECGs should be collected prior to any blood draws 
scheduled at the same time point, and ECGs should preferably be collected before (rather than just after) meals.  
ECGs may be obtained at additional times, when deemed clinically necessary.
gAll sample times are relative to the administration of the drug cocktail, except for the trough abemaciclib 
samples.  PK sample collection times are nominal; actual time s should be recorded.  Separate blood samples, 
2mL each, will be collected for the drug concentration measurements of abemaciclib, caffeine, 
dextromethorphan, midazolam, and warfarin.
hObtain o nly once after enrollment and eligibility is confirmed.   This sample can be taken during the baseline visit 
or at Predose Period 1, Day 1 once eligibility is confirmed.  
iRadiological tumor assessment can be omitted if prior scan is within approximately 4 weeks.  See Section 8.3for 
additional information.
j Serum creatinine only.
kThe first dose of abemaciclib on Day 1 should take place at the study site.  Patients will report to the study site on 
Day 8 and will be coadministered abemaciclib and the drug cocktail in the morning.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 82
Abemaciclib (LY2835219)lIncludes 2 blood samples collect ed for central laboratory assessment of renal markers in serum.
mTo include the recording of the use of alcohol, tobacco, nicotine replacement therapy, and caffeine.
nIf warfarin is not dosed in Period 2 cocktail, the INR sampling throughout Period 2 is not required; however, the 
INR may be assessed at the investigator’s discretion for safety purposes.
oPatients will be provided with a paper diary in which to record the start and stop times of all AEs, new 
concomitant medications and medications taken as needed from the baseline visit until the end of Period 2.
pIf warfarin is not dosed in Period 2 cocktail, the warfarin PK sampling throughout Period 2 is not required.
qDate and time of informed consent will be recorded.
rThe 8 -hour postdose sample may be drawn within ±2 hours (thus, at the 6 hour postdose or 10 hour postdose 
time point at the discretion of the site).  The actual time of collection must be recorded. 
sCocktail may be administered without warfarin in Period 2 if patient has an INR >2 af ter receiving warfarin in 
Period 1 (Section 7.2.1 ).
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 83
Abemaciclib (LY2835219)Study I3Y -MC-JPCB Study Schedule for Periods 3 and 4
Study DayPeriod 3
Cycle 1, Days 13 -28Period 4a
Cycle 2Follow -upb
Directed physical exam & 
ECOG statusX X
Vital signs c& weight XcX
Renal biomarkers Days 1, 14f, 28
Bowel habit/dosing 
Patient diaryX
(Daily )Daily  
(Day s 1 through 28)g
Bowel habit 
Patient outcomesDays 14, 21 Days 1, 7, 14, 21, 28d
Hematology & serum 
chemistryDays 1, 14f, 28 X
AEs & con meds X X X
Abemaciclib Q12H X Daily
Tumo r assessment XeX
Abbreviations:  AE = adverse event; con meds = concomitant medications; ECOG =Eastern Cooperative Oncology 
Group; exam = examination; Q12H = ever y 12 hours.
aPatients will be required to return to the site on Day 1 of each 28 -day cycle (±4 days).
bFor patients who will not participate in the safety extension, the follow -up assessment will occur approximately 
10 days after the end of the second cycle.
cVital signs will be collected before any blood samples at the s pecified time.  Supine ,orsemi-recumbent , or 
sitting blood pressure, heart rate, and temperature will be obtained.
dCycle 2, Day  28 patient outcomes may be completed before any procedures on Day 1 of Cycle 3.
eRadiological tumor assessment should be per formed on Day 28 (±14 days).
fCycle 2, Day  14 labs (+/ -2 days).
gPatient diary will extend through the end of Period 4 if longer than 28 days.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 84
Abemaciclib (LY2835219)Study I3Y -MC-JPCB Study Schedule for Safety Extension Phase
Study DaySafety extension: 
abemaciclib aFollow -upb
Directed physical exam & 
ECOG statusX X
Vital signs c& weight X X
ECG e X
Hematology, serum 
chemistry , & urinalysisX X
AEs & con meds X X
Abemaciclib 
administration X
Tumo r assessment Xd X
Abbreviations:  AE = adverse event; con meds = concomitant medications; ECG = electrocardiogram; 
ECOG = Eastern Cooperative Oncology Group; exam = examination.
aPatients will be required to return to the site on Day 1 of each 28 -day cycle (±4 days).
bFor patients participating in the safety extension, the follow -up assessment will occur approximately 10 days 
after the planned end of the last cycle.
cVital signs will be collected before any blood samples at the specified time.  Supine ,orsemi-recumbent , or 
sitting blood pressure, heart rate, a nd temperature will be obtained.
dRadiological tumor assessment should be performed on Day 28 (±14 days).  Imaging studies should be 
performed at the end of ever y 2 cycles (approximately every 4 to 8 weeks) up until 30 days after final 
abemaciclib dose, w hen another therapy is initiated, when there is disease progression, or w hen the patient dies
per standard of care until objective progression is observed based on the efficacy measurement criteria described 
in Section 8.3.  If a patient is discontinued fr om the study, repeat radiology may be omitted if progressive disease 
can be documented quantitatively with clinical measurements.
ePatients must be supine or semi -recumbent for approximately 5 to 10 minutes before ECG collection and remain 
supine or semi -recumbent but awake during ECG collection.  ECGs should be collected prior to any blood draws 
scheduled at the same time point, and ECGs should preferably be collected before (rather than just after) meals.  
ECGs may be obtained at additional times, when d eemed clinically necessary.
I3Y-MC-JPCB(d) Phase 1 Oncology Protocol Page 85
Abemaciclib (LY2835219)Clinical Laboratory Tests
HematologyaClinical Chemistrya
Hemoglobin Sodium
Hematocrit Potassium
Erythrocy te count (RBC) Total and direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils Alanine aminotransferase 
Lymphocy tes Aspartate aminotransferase 
Monocytes Gamma -glutamyl transpeptidase
Eosinophils Blood urea nitrogen 
Basophils Creatinine
Platelets Uric acid
Calcium
Coagulation parametersa, fGlucose, random
aPTT Albumin
PT Total protein
INR Magnesium
Phospho rus
Chloride
UrinalysisaLactate dehydrogenase
Specific gravity Osmolality
pH
Protein Renal Biomarkersb
Glucose Cystatin-C c
Ketones NGAL c, d
Blood KIM -1 d
Urine leukocyte esterase Creatinine c, d
Serum Urine Pregnancy Test
(females of child bearing potential only)
CYP2C9, CYP2D6, CYP3A4, and CYP3A5 
genotypinge
Abbreviations:  RBC = red blood cells; WBC = white blood cells; aPTT = activated partial thromboplastin time, 
CYP = cytochrome P450; INR = international normalized ratio; KIM -1 = kidney injury molecule -1; 
NGAL =neutrophil gelatinase -associated lipocalin; PT = prothrombin time.
aPerformed by local laboratory for safety management and the central laboratory for reporting purposes at all 
timepoint, except screening when only a local laboratory will be used.
bPerformed by a central laboratory (not performed at screening).
cVenous blood samples will be collected for serum tests.
dUrine samples (at least 5 mL and up to 120 mL) will be collected and tested.
ePerformed at baseline only
fCoag ulation parameters need not be measured in Period 2 if warfarin is not included in the Period 2 drug 
cocktail.
Leo Document ID = 4281776f-5521-496b-a75e-7e6c59715252
Approver: 
Approval Date & Time: 22-Sep-2016 13:28:45 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 22-Sep-2016 19:24:29 GMT
Signature meaning: Approved
PPD
PPD